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Why have we written this book?
We will all die one day. Death itself cannot be prevented, though the time at which we die may be postponed through effective 
prevention and treatment. But many people invest huge emotional 
energy in the idea that their eventual cause of death might somehow 
be avoided. The very Australian idea of the “good innings” often gets 
lost in all this. If you ask people to imagine their preferred form of 
death, many talk about something “quick” where there would be no 
time to anticipate what lay ahead and no pain. However, most would 
talk about peacefully dying in their sleep, at a late stage in life, after a 
life largely free of disease and disability, allowing them to enjoy their 
later years with good mobility, free of pain, having seen their family 
and grandchildren grow up, and leaving their affairs in order. Such 
a death would probably mean dying suddenly from a heart attack or 
cerebrovascular disease (stroke). 
Few people would ever nominate cancer as their preferred cause 
of death. Cancer and its recurrence [1] has become more feared 
than almost any other disease. Literature and cinema [2] are full of 
fearful references to cancer as a wasting, painful and ugly disease 
that slowly erodes the body, spreading inexorably and depressing 
everyone around the person suffering the disease. The word 
“cancer” has become a metaphor for something loathed, rotten and 
uncontrollable. We speak of cancer “invading” the body. We speak 
of a prevalent negative attitude or development as a “cancer” in the 
community. Crumbling buildings are said to have concrete cancer. 
6In 1971 US President Richard Nixon famously declared “war” on 
cancer [3], and the language of both cancer control and cancer 
patienthood is full of battle, heroic and stoic metaphors about 
struggles, fighting and defeating the disease [4, 5]. Cancer seems to 
attract such language more than any other disease and this has an 
impact on both the anticipated and lived experience of cancer.
Being told that you have cancer can be devastating: dreaded news 
that can preoccupy those diagnosed, seriously eroding quality of life, 
and causing depression [6]. Many cancer control agencies now refer 
to the experience of living with cancer as “the cancer journey”. This 
journey always starts with the patient being told that they have cancer. 
Once that news has been received, it stays with you for the rest of 
your life. Being told that you have cancer is not trivial information. It 
holds potential to start a sometimes rapidly unfolding train of events 
that may fundamentally alter the course and quality of your life. The 
main goal is often to fight and defeat the cancer that has suddenly 
been announced as a very unwelcome intruder in your body. The 
cancer will typically be surgically attacked and/or bombarded with 
radiation and highly toxic chemotherapies, all in the cause of the 
self-evidently important goal of stopping it from killing you. 
Against this, the idea that many men might have discoverable cancer 
in their bodies and yet may decide to not take steps to discover it is 
almost heretical to everything we have come to know about health, 
medicine and fighting disease. But this is a decision that many highly 
informed men are taking today about prostate cancer. Far from being 
simply dismissed as scared or ignorant screening “refusniks” – men 
who just need more support or persuasion to get tested – many men 
have taken what is for them a rational, evidence-based decision to 
choose to remain ignorant of whether they might already harbour 
prostate cancer in their bodies. 
7In taking this decision, these men are not eccentric mavericks 
but are in fact reflecting the overwhelming body of expert global 
consensus about whether it is a sensible thing to have all middle-
aged and older men – apparently free of the disease (that is, with 
no symptoms) – routinely tested for prostate cancer. There are now 
a large number of expert cancer and other public health agencies 
which have assessed the net risks and benefits of screening large 
numbers of asymptomatic men for prostate cancer to see whether 
population-wide activity driven by such a policy would actually save 
lives.
Many governments have formally adopted policies of cancer 
screening in particular age groups for different diseases. In Australia, 
the Commonwealth government has formally adopted a policy of 
targeting screening for breast cancer in women aged 50–69 and 
colorectal cancer in people aged over 50. It has long advocated that 
sexually active women be screened for cervical cancer by having Pap 
smears. 
While some prominent Australian urologists are very active in talking 
up the importance of prostate cancer screening, few Australians 
would be aware that no government anywhere in the world has a 
formal policy supporting prostate cancer screening. Nor would they 
be aware that aside from some professional urological societies, no 
reputable cancer control or expert prevention agency anywhere in 
the world currently recommends screening for the disease. Here are 
just a few illustrative examples: 
•	 The Australian government’s Australian Health Technology 
Advisory Committee examined the case for population 
screening for prostate cancer and in its 1997 report [7], did 
not recommend it. Thirteen years on, it has not changed that 
recommendation.
8•	 No state Cancer Council nor their national body, the Cancer 
Council Australia supports screening: “The Cancer Council 
supports expert reviews that current evidence does not support 
population screening of well men for prostate cancer.” [8]
•	 The Royal Australian College of General Practitioners: “Routine 
screening for prostate cancer with digital rectal examination 
(DRE), Prostate Specific Antigen (PSA) or transabdominal 
ultrasound is not recommended.” [9] 
•	 The American Cancer Society: 
The American Cancer Society recommends that men make 
an informed decision with their doctor about whether to be 
tested for prostate cancer. Research has not yet proven that 
the potential benefits of testing outweigh the harms of testing 
and treatment. The American Cancer Society believes that 
men should not be tested without learning about what we 
know and don’t know about the risks and possible benefits of 
testing and treatment. [10]
•	 British Columbia’s Cancer Agency in Canada: 
PSA testing is of unknown value as a population screening 
test. Although there is good evidence that it increases the 
detection rate of early stage, clinically significant prostate 
cancers, there is little evidence to date that such early 
detection leads to reduced mortality; the “gold standard” for 
evaluating screening tests. [11]
•	 The UK’s National Screening Committee: “The UK NSC does 
not recommend screening men for prostate cancer.” [12]
•	 The US Preventive Services Task Force: 
The USPSTF concludes that the current evidence is 
insufficient to assess the balance of benefits and harms of 
prostate cancer screening in men younger than age 75 years. 
9The USPSTF recommends against screening for prostate 
cancer in men age 75 years or older. [13]
•	 The Prostate Cancer Foundation of Australia (PFCA) is an 
example of one of the few agencies which do support screening. 
Its policy states:
PCFA recommends that men at 50 with no family history of 
prostate cancer, and men at 40 with a family history, should 
seek voluntary annual assessments in the form of a Prostate 
Specific Antigen (PSA) blood test together with a Digital 
Rectal Examination (DRE). [14]
Despite this international expert consensus, de facto screening of 
populations is well under way, being driven by well-meaning advice 
about the importance of having men becoming more informed 
about their health. “Women have their cancer tests, men have theirs” 
runs the simplistic argument at its most basic level. 
A 2003 review of the issue in the Lancet concluded that if one million 
men over 50 were screened, 
about 110,000 with raised PSAs will face anxiety of possible 
cancer, about 90,000 will undergo biopsy, and 20,000 will be 
diagnosed with cancer. If 10,000 of these men underwent 
surgery, about 10 would die of the operation, 300 will develop 
severe urinary incontinence and even in the best hands 4000 
will become impotent. 
And then came the crunch: 
The number of men whose prostate cancer would have 
impinged on their lives is unknown. [15]
This neat summary encapsulates why this issue is so important. 
Men are being increasingly urged by some to subject themselves to a 
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medical procedure that may dramatically reduce their quality of life 
by causing impotence and incontinence. But the evidence that this 
procedure will in fact save men’s lives is by no means well established, 
while the risks are known and very real.
By 2003 (the latest date from which published estimates are 
available), around 50% of Australian men aged 40 and over were 
estimated to have been tested for prostate cancer [16]. With high 
profile promotion of screening through campaigns like Movember, 
and men being urged to take the test by campaigns organised by 
the Prostate Cancer Foundation of Australia, this proportion would 
be considerably higher today in 2010. But many men consciously 
choose not to be tested.
This book tries to explain why many men make that decision. It 
seeks to bring their reasons out into the open, and repudiates the 
facile idea that men who elect not to be tested are nothing more 
than unmanly “pussies” who are squeamish about having a doctor 
put a finger up their rectum to feel for prostate enlargement or who 
are just indifferent to protecting their health. This sort of trivialising 
focus has been a prominent part of campaigns in Australia with 
slogans like “Be a man!” designed to get men to be screened. Comic 
actor Magda Szubanski, whose father died of the disease, told the 
national 60 Minutes TV audience in 2007: “Don’t be a pussy. Go and 
get the check” [17].
Our aim in this book is to provide a detailed examination of the 
main questions that a man should be asking before deciding to get 
tested. Deciding to have a PSA test can quickly lead to a course of 
events that for some men may save their life. But as we will show, 
for many more a test will result in serious, unnecessary surgery and 
other interventions. In a large proportion of cases, this will cause 
enduring and often permanent, major after-effects in the form of 
sexual impotence, urinary incontinence and less commonly, faecal 
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incontinence. The surgery will have been unnecessary because – 
strange as this idea may seem – the cancer would have never caused 
problems in many of these men’s lives. This is an absolutely central 
point that is at the heart of this book. 
The other core point we will make is that medical science is today 
unable to predict with any precision which early discovered prostate 
cancers will turn out to be those that kill, and particularly which 
will kill men in middle age. Many people have deep faith in medical 
science. They believe that diagnostic tests undertaken by doctors and 
pathologists can provide highly reliable information that can predict 
with great precision the likely progress of a disease like cancer. Often, 
this is true and often people have experienced this when a diagnostic 
test has led to an effective form of therapy that has cured a disease 
in them or other family members. So when a much-promoted test 
turns out to have major shortcomings in its ability to accurately 
point to a cancer that urgently needs attention, it is understandable 
that many would find this news hard to believe. But as we will see 
(p58), the frontline diagnostic tool in efforts to screen for prostate 
cancer – the PSA test – is a tool which has very poor ability to find 
problematic cancers. It finds many benign cancers which could have 
been left alone. 
Prostate cancer is the second most common cause of cancer death in 
Australian men (after lung cancer). Like deaths from nearly all forms 
of cancer – but even more so in the case of prostate cancer – the 
large majority of men who die from the disease die late in life (see 
p31) close to when they would have in all probability have died from 
another cause anyway. For many, the idea that one might decide to 
not take every possible step to catch this cancer early is nothing less 
than bizarre. But in the zeal to wage war on cancer, we now know 
there are many avoidable casualties: people who get caught up in 
whirlwind of unnecessary medical intervention from which it is 
difficult to withdraw.
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In Australia today, there are many thousands of men who have 
had their prostates removed and who, as a result, are permanently 
sexually impotent (meaning that they are unable to attain an 
erection sufficient for intercourse). Some of these men, and others 
who are not impotent, also have ongoing incontinence problems. 
These are not problems that you wear on your sleeve, or announce 
to the world. They are typically endured privately and rationalised 
by the very powerful idea that these problems were small prices 
to have to pay to remain alive. A small minority of these men may 
be right in thinking this: but for having found their cancer early, 
and having their prostate removed, they might well be dead. But as 
we will see, there is a great number of individuals who have been 
treated unnecessarily for the disease. It would not have killed them 
and they now live with the consequences of having that unnecessary 
treatment. 
Some men who have had their prostates surgically removed become 
determined and committed advocates for prostate cancer screening. 
Many see them as powerfully convincing, living proof-of-the-
pudding that early detection saves lives. After all, they have lived to 
tell the tale. But as we shall explore, for every such man whose life was 
saved as a result of early detection, there can be up to 47 more [18] 
who in all probability would not have died as a result of the cancer 
that was found. For many of these men, their sexual impotence, their 
incontinence and their enduring anxiety that the cancer may have 
spread in undetectable ways and may return in other parts of their 
body are legacies that could have been avoided. 
Australia has seen febrile, often acrimonious debate on prostate 
cancer screening. In February 2003, an interview with Professor 
Alan Coates, then chief executive of the Cancer Council Australia 
and aged 59, was published in the Australian Financial Review. He 
stated that he had personally chosen to not have a PSA test, arguing 
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[t]he test may find things that didn’t need to be found or it 
may find things when it is too late to fix them. The supposition 
is that there is a group in between where it finds something 
early enough to make a real difference, but there is no proof 
that such a window of opportunity exists. [19]
The article generated widespread, overwhelmingly negative 
responses from several Australian urologists and cancer survivors, 
including two federal politicians who were incendiary in their 
criticism, particularly from within the safety of parliamentary 
privilege [20]. An editorial called Coates “the apostate professor” 
whose actions will have “confused thousands of men” [21]. Coates 
protested that to be an apostate, one must have once believed [22].
This very public row would have been noticed by millions of Aus-
tralians used to encountering cancer control officials (including 
Coates) enthusiastically promoting population screening for cer-
vical, breast and colorectal cancer, and stressing the importance of 
early detection. Yet here was one of the nation’s most senior cancer 
experts saying that he personally had taken the decision to not be 
tested. Why, many would have asked, should the case for the early 
detection of prostate cancer be any different than for other cancers?
The message about the importance of early detection for saving lives 
has been driven home over many years through public awareness 
campaigns for many diseases. The idea has taken on something of 
the status of a commonsense law, admitting no challenge. Unsur-
prisingly, a recent study found that over two-thirds of Victorian 
adults believed their chances of surviving prostate cancer would be 
very much improved by early detection [23]. US survey evidence 
shows 87% of adults believe that routine cancer screening is almost 
always a good idea and that finding cancer early can save lives (74% 
said most or all of the time). Moreover, 77% of men said that they 
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would try to keep having a PSA test even if a doctor recommended 
that they stopped having or had less frequent testing [24]. 
There are also studies that show that when men are better informed 
about prostate cancer their interest in screening goes down. For ex-
ample, an Australian study considered men who were visiting their 
GP who were sent balanced information about the pros and cons of 
PSA screening. Before receiving the information, about 50% of men 
were definitely interested in being screened, but afterwards, only 
24% reported being definitely interested [25]. In an earlier US study, 
men scheduled for a routine visit to their doctor were randomly 
divided into some who were shown a video about the pros and cons 
of PSA screening and others who did not watch the video. Men who 
saw the video were less likely to want the test afterwards, (30% in the 
video group, compared to 67% in the control group), and fewer went 
ahead with the test at the next opportunity (12% in the video group 
compared to 23% in the control group) [26]. There are two other 
studies like these, with similar findings [27, 28] and one [29] which 
found information about the pros and cons of screening made no 
difference to the percentage of men who chose to be screened. 
A senior cancer control figure like Alan Coates publicly declaring 
that he personally would not be tested would thus have appeared to 
many as heretical and counterintuitive. But Coates was no Robinson 
Crusoe: he was not alone in his decision. Just as many men elect to 
be tested for prostate cancer, an equally if not larger number of well-
informed men are today electing not to be tested on the basis of the 
currently available scientific evidence. Many make similar decisions 
to not undertake genetic screening for a range of diseases which may 
provide unwelcome information of doubtful use.
We have written this book to provide the hundreds of thousands 
of Australian men facing the decision about whether to get tested 
for prostate cancer with important information that many of them 
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would not have encountered before. Public discussion about prostate 
cancer screening in Australia today is overwhelmingly dominated 
by pro-screening voices, many of whom have obvious vested inter-
ests in promoting widespread testing and medical intervention (see 
p112). As we will show, while it is almost standard for all parties to 
this debate to emphasise the vital importance of men being informed 
about the pros and cons of prostate cancer screening, attention to the 
“cons” has been woefully neglected or avoided by many actively pro-
moting screening. 
Prostate screening advocates often include men diagnosed and 
treated for prostate cancer, urologists and some non-government 
advocacy groups, including those supported by the manufacturers 
of prostate cancer diagnostic tests and treatments. These advocates 
have sometimes been aggressive in attacking those who have 
expressed reservations about the wisdom of screening [30]. In 
2001, the editors of the US-based Western Journal of Medicine were 
subjected to particularly vicious lobbying and character assassination 
following cautious remarks they made in The San Francisco Chron-
icle newspaper about prostate cancer screening. Efforts were made 
to have them dismissed from their roles, and they were said to be 
promoting ”geriatricide”: the killing of aged men [31].
In 2003, when one of us (SC) wrote to a Federal Member of Parlia-
ment, Jim Lloyd, questioning a letter he had written to The Sydney 
Morning Herald claiming that “there was now less than a 4 per cent 
chance of incontinence” following treatment for prostate cancer, Mr 
Lloyd replied that “many academics place far too much reliance on 
statistics and forget the human aspects. Whilst you continue to study 
your surveys, figures and databases I will continue to deal with real 
issues.” He included (with permission) a letter from Dr Phillip Kate-
laris (who said Lloyd was welcome to forward his letter to the press). 
Katelaris described SC as “a man quite divorced from the anguish 
of prostate cancer, a non-feeling egocentric ‘past president of the 
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Australian Consumers’ Association’.” This will give readers a flavour 
of both the sometimes very personal nature of the debate and the 
disdain that some have for evidence across large numbers of men, 
seemingly preferring to base health policy on the apparent benefits 
that have occurred for individual men who are personally convinced 
that prostate screening saves lives.
High profile campaigns like Movember reflect none of this debate. 
Movember’s website states 
We want everyone to know that men over the age of 50, and 
those over 40 with a family history, are at risk of prostate 
cancer and encourage them to be tested annually because it 
is highly curable if detected and treated early. [32]
We often hear urologists and prostate cancer advocacy groups via 
campaigns like Movember urging that men should be screened. Far 
less often, we hear others urging that men should not rush into it 
and think very carefully about both the benefits and risks. All agree 
that it is a decision that should be talked over with one’s doctor. But 
with waiting room queues putting pressure on a doctor’s time, such 
conversations about such major decisions can often be rather short 
and leave a lot of questions unexplored.
In this book we will examine what is actually meant by being “at 
risk” for prostate cancer and also the evidence driving the proposal 
that men should be tested every year for the disease. We will look in 
detail at the results of a nine-year multi-nation European trial pub-
lished in 2009 [18] and a 14-year Swedish trial published in 2010 
[33, 34] which sought to answer the question of whether men who 
are screened for prostate cancer have a lower death rate from the 
disease than men who do not get screened. We will look at very re-
cent evidence from Australia about what men undergoing treatment 
for prostate cancer can expect in terms of continuing sexual func-
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tion and continence. Finally, we will look at claims made by some 
surgeons about the alleged greatly reduced risks of impotence and 
incontinence when “robotic” surgical techniques are used in laparo-
scopic (“keyhole”) surgery for prostate cancer. As we will see, men 
should treat these claims with a good deal of circumspection.
Finally, we feel it is important to say something about claims that 
are often made about “percentage change” in outcomes like death or 
adverse side effects. There are two ways that change can be expressed 
in ordinary language: relative change and absolute change. Consider 
the case of smoking. Imagine if in the first year of a study 25% of 
adults smoked, and 10 years later, when the same group were again 
questioned, 18% now smoked. The absolute difference between 25 
and 18 is 7% or a fall of 1.43% per year. But the relative difference is 
28% or 2.8% a year (a reduction of 7% off a baseline of 25% is 28% 
less). Twenty-eight per cent sounds more impressive and is likely 
to be the figure that anyone would select who wanted to “talk up” 
the improvement. Those wanting to talk down the progress to re-
duce smoking – for example, to argue for stronger legislation and 
campaign funding – would probably emphasise the absolute, smaller 
figure in an effort to promote concern that not enough was being 
done.
Those selecting absolute or relative measures are often not explicit 
in what they say, particularly when a complex study is reported in 
the news media in just a few sentences. We have often noticed this 
in public discussions about prostate cancer. Sydney man-about-
town, lawyer and newspaper columnist Charles Waterstreet wrote 
in his Sunday newspaper column in November 2009 that “Extensive 
PSA screening in other countries has meant a 40 per cent fall in the 
mortality rate” [35]. Newspaper writers rarely cite their sources, and 
Waterstreet was no exception here. But if he was referring to the 
2009 New England Journal of Medicine European trial [18], the claim 
for “40% fall in mortality” is quite misleading. The fall was 20% in 
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relative terms derived from data obtained over nine years of follow-
up that showed there were 2.94 deaths per 1000 men in the group 
of screened men compared with 3.65 deaths per 1000 men in nine 
years (see p98).
A recent US survey [36] of medical decisions specifically looked at 
the decision US men made with their doctors about PSA screening. 
The survey included 375 men who had been tested in the previous 
two years (85%) and men who had discussed having the test but 
had not actually gone ahead with the test (15%). Of these men, 70% 
reported their doctor had discussed the test with them before a 
decision about testing was made; 94% said the doctor had discussed 
the “pros” of having the PSA test, only 32% reported the doctor had 
discussed the “cons” of the test. Sixty per cent reported they shared 
the decision with their doctor, 32% said they had made the decision 
and 8% said the doctor had made the final decision. 
The final decision will always be yours. We hope the information 
we have set out in the book will make that decision a much better 
informed one than it might otherwise have been.
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1What is prostate cancer and how common  
is it?
The prostate is an exocrine (secreting) gland in the male reproductive system. It surrounds the urethra just below the 
bladder and can be felt indirectly behind the rectal wall by a finger 
inserted into the rectum (this is known as digital rectal examination 
or DRE). A healthy prostate is slightly larger than a walnut. The 
prostate stores and secretes a milky fluid that makes up 25–30% 
of the semen volume, along with spermatozoa and seminal vesicle 
fluid. Prostatic fluid is expelled in the first ejaculate together with 
most of the spermatozoa. 
Three main diseases can afflict the prostate: prostatitis, benign pros-
tatic hyperplasia (BPH) and less commonly, prostate cancer.
Prostatitis is inflammation of the prostate gland. Prostatitis is a 
very common problem, which occurs particularly, but by no means 
exclusively, in older men [37]. Typical symptoms of prostatitis 
include fever, chills, increased urinary frequency, frequent urination 
at night, difficulty in urinating, burning or painful urination, 
pain between the anus and the scrotum (perineal pain), low-back 
pain, a tender or swollen prostate, blood in the urine, and painful 
ejaculation. 
The best understood cause of prostatitis is infection with the same 
kinds of bacteria that cause other kinds of urinary tract infection. 
Acute bacterial prostatitis typically affects younger men, or those 
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with a urinary catheter, and often causes severe symptoms. Chronic 
prostatitis typically affects middle-aged or older men, often causes 
few symptoms, and is typically found as a cause of recurrent urinary 
tract infections. Bacterial prostatitis is treated with antibiotics.
Chronic non-bacterial prostatitis or male chronic pelvic pain 
syndrome, is the diagnosis given to the 95% men who have some 
symptoms of prostatitis, but no evidence of bacterial infection [38]. 
Many treatments have been tried for this poorly understood set of 
symptoms, but those tested carefully, including with alpha blockers, 
anti-inflammatories, and alternative therapies, have shown only 
modest benefits at best [39].
Benign prostatic hyperplasia (BPH) occurs in older men. With 
ageing, the prostate often enlarges to the point where urination 
becomes difficult. Symptoms include needing to urinate often or 
delayed commencement of urination. If the prostate grows too large, 
it may constrict the urethra and impede the flow of urine, making 
urination difficult and painful, and in extreme cases completely 
impossible. The prostate gets larger in most men as they age. A large 
European study showed the prevalence of BPH is 2.7% for men aged 
45–49, increasing to 24% by the age of 80 [40].
BPH can be treated with medication, a minimally invasive surgical 
procedure or by surgery that completely removes the prostate. 
Minimally invasive procedures include transurethral needle ablation 
of the prostate (TUNA) and transurethral microwave thermotherapy 
(TUMT). The surgery most often used for obstructive BPH is called 
transurethral resection of the prostate (TURP or TUR). In TURP, a 
surgical instrument is inserted into the penis through the urethra 
and small sections of the prostate that are pressing against the upper 
part of the urethra and restricting the flow of urine are shaved off 
from the inside, reducing the pressure on the urethra. The procedure 
is often colloquially known as a “rebore”.
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Prostate cancer is a common cancer, affecting about 20% of men 
by the age of 85. It is uncommon in young men (under 50) and 
becomes increasingly common as men age. In fact, autopsy studies 
show that a significant proportion of men (around 40–50%) – have 
prostate cancer by the age of 70. These men had no idea they had 
prostate cancer, so we know that prostate cancer occurs commonly 
and can cause no symptoms at all. Prostate cancer is the cause of 
death in only about 4% of men. Since it occurs in up to 50% of men, 
we therefore know that in many, many men it is not life threatening 
(see below). 
Early prostate cancer causes few symptoms. In fact there are no 
symptoms that can differentiate prostate cancer from benign prostate 
diseases such as benign prostatic hyperplasia. Just like BPH it can 
cause problems with urination and erectile function. 
Usually prostate cancer grows very slowly (see indolent cancer below) 
but what we call “prostate cancer” includes a spectrum of disease 
from slow-growing cancers through to rarer cancers that grow and 
spread more rapidly. Prostate cancer cells may metastasise (spread 
or disseminate) from the prostate to other parts of the body, such as 
the lymph nodes, bones, lungs and liver. Prostate cancer cells that 
spread to other parts of the body can cause significant symptoms, 
most commonly bone pain and fatigue. Prostate cancer that has 
spread to other parts of the body is incurable and usually fatal, but it 
is also treatable so that unpleasant symptoms can be reduced. Most 
men with metastatic prostate cancer live several or more years after 
it is diagnosed.
What is an “indolent” cancer?
“Indolent” means slow growing. Many may be surprised to learn 
that cancer can exist in the body for many years without ever 
becoming a problem. Thyroid cancer and lymphomas are examples 
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of cancers which are found in people but can be indolent and non-
life threatening. We know from autopsy studies that they may exist in 
the body for many years without causing any problems to a person. 
More on autopsy studies shortly.
In the past 30 years in the US, the incidence of thyroid cancer 
doubled while the death rate from the disease remained stable 
[41]. As we will see in detail later, this is also the case with prostate 
cancer: nearly all of this large increase in cancer incidence – 87% 
with thyroid cancer – can be explained by advances in diagnostic 
and imaging technology that enable thyroid cancer to be discovered. 
These developments have seen small papillary cancers being found 
that would have not been found with earlier diagnostic techniques. 
As diagnostic technology becomes more and more sophisticated and 
precise, evidence of disease can be found that in past times would 
have not come to light. 
With prostate cancer, massive increases in the number of men 
being tested for the disease have resulted in large increases in the 
incidence of the disease. But just like thyroid cancer, the death rate 
from prostate cancer has remained remarkably stable for nearly 40 
years in Australia. 
Some reading this will immediately think “isn’t it wonderful that 
advances in science have allowed us to detect these cancers earlier, 
so they can be treated sooner and save lives.” Such thinking risks 
missing the point that the whole aim of medical investigation is to 
find and treat problems which threaten health and life. If a “problem” 
does neither, we need to ask why it should be thought of as a problem. 
The authors of the thyroid study above commented that “many of 
these cancers would likely never have caused symptoms during life” 
and the burgeoning incidence of thyroid cancer is a classic example 
of “overdiagnosis” [41]. 
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Overdiagnosis means the diagnosis of conditions which would have 
never caused a person distressing problems of ill-health or death. 
It means conferring a disease label on people who are living lives 
untroubled by that disease and more importantly, who are unlikely to 
be ever troubled by that disease. Prostate cancer has been described 
as the par excellence example of overdiagnosis. This does not mean 
that there are not men whose lives are saved from early death from 
prostate cancer by early diagnosis. But as we shall see throughout 
this book, we have little way of knowing in advance which men will 
benefit from screening and which will be unnecessarily treated, often 
with serious adverse consequences to their life. The fundamental 
problem is that by screening and testing for prostate cancer we are 
finding many more prostate cancers than we ever did before, and 
strange as it may seem, many of these cancers would never become 
life threatening. In the past these men would never have known 
they had prostate cancer, they would go on to die of something 
else, dying with their prostate cancer, rather than because of it. By 
finding all these prostate cancers that are indolent we are giving 
many more men a prostate cancer diagnosis than ever before. Hence 
the term “overdiagnosis”. This is the core dilemma that each man 
contemplating being tested faces.
What do autopsy studies show?
One way of estimating the extent of overdiagnosis in a community is 
via the results of autopsies carried out on people who have died while 
not under medical care. Autopsies are performed to determine cause 
of death when this has not already been established by diagnosis prior 
to death occurring, but can also reveal the presence of symptomless 
disease that was not causing the person any problems. These studies 
provide a unique way of estimating the prevalence of undiagnosed, 
often benign disease in a population. This is because people who die 
suddenly, while not being a random sample, nonetheless represent 
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a wide cross-section of the population. Sudden deaths may occur 
more in men with dangerous occupations and who have risk factors 
for heart disease. These factors may introduce unknown biases 
that might cause the prevalence of prostate cancer to be lower or 
higher than in a truly random sample of the population. But the 
nature and direction of such biases are not obvious, and so it is 
likely that the picture we get from autopsy studies will provide a 
broadly accurate estimate of the prevalence of undetected prostate 
cancer in the community. Because we can compare the prevalence of 
symptomless prostate cancer found at autopsy with how many men 
develop prostatic cancer that causes symptoms and then die of it, 
we can get a broad estimate of the extent of overdiagnosis. In other 
words, autopsy studies can show us that there are some diseases 
which commonly don’t cause symptoms at all, much less threaten 
life. And the prevalence of such disease is quite high.
Autopsy studies of Chinese, German, Israeli, Jamaican, Swedish, and 
Ugandan men who died of other causes (such as sudden death through 
injury, homicide, suicide or heart attack) have found prostate cancer 
in 10–20% of men in their 50s, and in a remarkable 40–50% of men 
in their 70s [42]. In a Pittsburgh (US) study of 340 sudden death 
victims who had donated their organs for transplantation, it was 
found that across all age groups combined, 12% of men had prostate 
cancer. From age 40, the proportion of men with evidence of the 
disease began to rise. Among men aged 50–59, 23% had incidental 
prostate cancer and among those aged 60–69, 35% (approximately 
one in three) had incidental prostate cancer. In the oldest group 
(aged 70–81) 46% of men were harbouring the disease [43]. 
These studies provide a unique way of estimating the prevalence of 
undiagnosed, often benign disease in a population. The take-home 
message from these studies is that benign, symptomless prostate can-
cer is very common in men, especially in later life. Men live without 
knowing they have the disease and most will never be affected ad-
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versely by it, dying of some other cause with “silent” prostate cancer 
having been in their bodies for many years. As prostate cancer did 
not kill these men, it is clear that finding and treating their prostate 
cancer would not have delivered any health benefit, nor extended 
their lives. 
2What is the risk of dying from prostate 
cancer?
We will all one day die of some cause that will be entered on our death certificate by our doctor or determined by a coroner if 
we have died suddenly without having been under recent medical 
care. In 2007, 70,569 men died in Australia out of a total male 
population of 10,358,791, meaning that 0.68% of men – around one 
in 147 – died in that year from any cause. Table 1 shows numbers and 
percentages of total deaths for the top 20 causes of death in males.
Table 1: Leading underlying specific causes of male death, all ages, 2007 
Rank Cause of death Number  
of deaths
% all  
male deaths
1 Coronary heart diseases 12,119 17.2
2 Lung cancer  4715 6.7
3 Cerebrovascular diseases  4516 6.4
4 Chronic obstructive pulmonary 
disease 
 2965 4.2
5 Prostate cancer  2938 4.2
6 Dementia and Alzheimer’s  
disease 
 2415 3.4
7 Colorectal cancer  2221 3.1
8 Diabetes  1923 2.7
9 Unknown primary site cancers  1832 2.6
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Rank Cause of death Number  
of deaths
% all  
male deaths
10 Suicide  1453 2.1
11 Heart failure and complications 
and ill-defined heart diseases 
 1361 1.9
12 Pancreatic cancer  1233 1.7
13 Kidney failure  1163 1.6
14 Influenza and pneumonia  1160 1.6
15 Liver diseases  977 1.4
16 Land transport accidents  948 1.3
17 Leukaemia 892 1.3
18 Melanoma 864 1.2
19 Oesophageal cancer 790 1.1
20 Lymphomas 780 1.1
All deaths 70,569 100.0
Source: Australian Institute of Health and Welfare National Mortality Database.
But what about prostate cancer as a cause of cancer death? Table 2 
below showing cancer incidence and death indicates that prostate 
cancer is the second highest cause of cancer death in men in Australia 
after lung cancer. With 2938 deaths out of 70,569 male deaths in 
2007, about 4.2% of all men’s deaths across all ages in that year were 
from prostate cancer. The probability of any given male of any age 
dying of prostate cancer in a single year was 0.03% or one in 3513. 
But as we will show below, this proportion is far larger for men in 
older age groups, because deaths from prostate cancer are very rare 
in men aged less than 40 and very uncommon in men aged less than 
50. Men aged over 50 are sometimes described as being “at risk” 
for prostate cancer, although some urologists have recently tried to 
widen that label to include men in their 40s (see p43).
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Table 2: New cases (incidence) of selected common cancers in males (2006) and 
mortality (2007) from those cancers, Australia 
New cases (incidence)
Cancer site/
type 
Number Per cent of 
total cancer
Crude rate per 
100,000 
Risk to age 85
Prostate 17,444 29.5 170.0 1 in 5
Colon 4566 7.7 45.9 1 in 16
Melanoma 6051 10.2 59.6 1 in 14
Lung, 
bronchus & 
trachea 
6030 10.2 60.6 1 in 12
Rectum 2866 4.9 28.3 1 in 27
Lymphoma 2518 4.3 24.7 1 in 33
Head and 
neck
2059 3.5 19.9 1 in 40
Bladder 1764 3.0 18.1 1 in 38
Kidney 1625 2.8 15.9 1 in 51
Leukaemia 1513 2.6 15.2 1 in 52
Stomach 1277 2.2 12.9 1 in 55
Pancreas 1158 2.1 10.2 1 in 70
All cancers 59,058 100.0 584.6 1 in 2
Deaths
Number Per cent of 
total deaths 
Mean age at 
death
Lung, bronchus 
& trachea 
4715 6.7 72.0
Prostate 2938 4.2 79.8
Colon 1295 1.8 73.0
Pancreas 1233 1.7 70.7
Rectum 896 1.3 70.6
Leukaemia 892 1.3 71.7
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Deaths
Number Per cent of 
total deaths 
Mean age at 
death
Melanoma 864 1.2 69.2
Oesophagus 790 1.1 69.3
Lymphoma 780 1.1 71.9
Stomach 704 1.0 71.6
Head and neck 667 0.9 68.3
All cancer  
except prostate
19,624 27.8 71.5
All cancers 22,562 32.0 72.6
Sources: www.aihw.gov.au/cancer/index.cfm and correspondence from AIHW 
dated 26 July 2010.
As we saw above, the risk of a man dying of prostate cancer in one 
year was a very low 0.03% or one in 3513, and about 4% of all men 
will die from prostate cancer. Mostly these deaths occur at advanced 
ages. A man’s chance of dying of prostate cancer increases with age. 
Table 3 shows the numbers, rates per 100,000 men and probabilities 
of death of prostate cancer in one year in Australia.
As can be seen in the first column of Table 3, of the 2938 men who 
died from prostate cancer in 2007, more than half (1716 or 58%) 
were aged 80 or over and 82% were aged 70 or more. Just 2.8% (83 
men) were aged less than 60, and 10 (0.1%) were in their 40s. The 
average age of death (note that this is a different concept than “life 
expectancy”) in men in Australia in 2007 was 76 years (see Table 
2). So men who die from any cause after that time are already living 
longer than average. The data in the US are remarkably similar. There, 
the median age of death from prostate cancer from 2000 through to 
2004 was 80 years, and 71% of deaths occurred in men older than 
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75 years [13]. These figures will surprise many men accustomed to 
reading about men of much younger age dying of prostate cancer. 
Some certainly do die in middle age, but compared with death rates 
from other cancers, relatively fewer men die from prostate cancer in 
middle age.
Table 3: Number and rate of prostate cancer deaths and probability  
of death in one year, Australia 2007
Age group and number of prostate 
cancer deaths
Rate per 100,000 and probability  
of death in one year
40–44#: 3 0.4 (1 in 250,000) 
45–49: 7 0.9 (1 in 111,111)
50–54: 18 2.6 (1 in 38,462)
55–59: 55 8.7 (1 in 11,494)
60–64: 142 26.6 (1 in 3759)
65–69: 215 53.8 (1 in 1859)
70–74: 315 101.1 (1 in 989)
75–79: 567 223.1 (1 in 448)
80–84: 713 413.8 (1 in 242)
85+: 903 800.9 (1 in 125)
All ages: 2938 31.0 (1 in 3226)
Source: www.aihw.gov.au/cancer/data/acim_books/index.cfm (prostate cancer) 
# no deaths were recorded in men less than 40
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What are the historic trends in prostate cancer deaths  
in Australia?
The total number of men dying in Australia from prostate cancer is 
increasing slowly each year. In the 39 years between 1968 and 2007, 
prostate cancer deaths grew from 963 to 2938, an average annual 
increase of 51 deaths per year, or one a week [44]. The two main 
reasons for this growth are that the age structure of the population 
is changing and the size of the population is growing. We have an 
aging population in Australia (the proportion of the total population 
in older age groups is steadily increasing). So both the number and 
the proportion of older people in the community are increasing as 
the post-World War II baby-boomer generation grows into old age. 
Moreover, because we have been so successful in reducing deaths 
from many causes of death that in past decades would have killed 
people earlier in life, many more men are surviving longer and so the 
numbers and proportions of deaths caused by diseases like cancer 
which tend to kill people later in life are rising. Life expectancy has 
increased. In 1950, male life expectancy in Australia was only 66.5. 
Today’s 79 years is a remarkable 18.8% increase on that, all in what is 
less than an eye blink of time in human history.
Major causes of death in men such as lung cancer, heart disease and 
motor vehicle injury have decreased dramatically in this period too. 
Because people have to die of some cause, reductions in some causes 
of death inevitably mean that more men will die from other causes 
instead. For example, if we want to see the rates per 100,000 of lung 
cancer deaths we see today in men, we have to travel back to 1962 [45]. 
However, by looking at the age-standardised death rate per 100,000 
men over time we get a very different picture, helpful in thinking 
about the question of whether this disease is really claiming “more” 
lives today. Age-standardised rates adjust for any changes in the 
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age distribution in the population over time and so allow a valid 
comparison of rates over time. Table 4 is worth studying closely. 
Several broad trends are obvious. First, in the 39 years 1968–2007, 
the age-standardised death rate from prostate cancer has varied 
very little, with an average of 35.8 per 100,000 men and a range of 
32.2 to 43.7. The most recent rate in 2007 (31 per 100,000) was very 
similar to the death rate at the beginning of this 38-year series in 
1968 (35.6/100,000). In between there was a rise in the death rate (in 
the early- to mid-1990s) which has now reversed back to rates seen 
in the early 1970s, a decade before the PSA test became available. 
(“Incidence” means the number of new cases of prostate cancer 
diagnosed in that year). 
However, looking at the data on cancer incidence, the same basically 
flat trend we see for deaths is not apparent. Instead we see a dramatic 
leap in the incidence of the disease from the early 1990s. This 
change has been largely sustained ever since, resulting in a startling 
difference in the risk of men being diagnosed with prostate cancer 
before the 1990s (approximately one in 22 men in their lifetime) to 
nearly three times that today (one in eight). 
These patterns are obvious in Figure 1 below. 
Two obvious questions arise here: what has caused this massive 
increase in the incidence of the disease? And if the death rates from 
the disease today are almost the same as they were 38 years ago 
when the known incidence of the disease was much lower, then what 
can be said about the relationship between the rising incidence of 
the disease and the failure of the death rate to change in the same 
dramatic fashion?
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Table 4: Age-standardised death and incidence rates of prostate cancer, 
1968–2006
Year Death rate per 
100,000
Risk to age 
75 of death 
from prostate 
cancer
Incidence rate 
per 100,000
Risk to age 75 
of prostate 
cancer being 
diagnosed
1968 35.6 1 in 78 National incidence data 
were not kept prior to 1982 
in Australia1969 33.4 1 in 77
1970 36.8 1 in 74
1971 32.6 1 in 84
1972 32.4 1 in 78
1973 34.1 1 in 70
1974 33.2 1 in 77
1975 34.3 1 in 83
1976 33.0 1 in 72
1977 34.0 1 in 78
1978 32.2 1 in 82
1979 33.6 1 in 72
1980 33.4 1 in 76
1981 33.4 1 in 79
1982 34.5 1 in 77 80.8 1 in 23
1983 34.7 1 in 82 80.1 1 in 24
1984 33.3 1 in 73 83.2 1 in 22
1985 35.7 1 in 80 82.9 1 in 22
1986 35.7 1 in 72 85.5 1 in 22
1987 37.2 1 in 73 85.7 1 in 22
1988 37.6 1 in 66 92.7 1 in 21
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Year Death rate per 
100,000
Risk to age 
75 of death 
from prostate 
cancer
Incidence rate 
per 100,000
Risk to age 75 
of prostate 
cancer being 
diagnosed
1989 39.6 1 in 68 102.7 1 in 20
1990 39.7 1 in 65 110.1 1 in 17
1991 39.3 1 in 68 124.1 1 in 16
1992 41.2 1 in 60 165.0 1 in 14
1993 43.7 1 in 62 184.2 1 in 9
1994 43.6 1 in 63 168.6 1 in 8
1995 41.2 1 in 63 137.6 1 in 8
1996 41.3 1 in 68 129.9 1 in 10
1997 36.8 1 in 74 128.0 1 in 11
1998 37.2 1 in 74 129.7 1 in 11
1999 35.2 1 in 82 128.4 1 in 11
2000 35.9 1 in 76 130.6 1 in 11
2001 35.2 1 in 82 134.5 1 in 11
2002 35.3 1 in 84 147.2 1 in 10
2003 34.5 1 in 80 164.3 1 in 9
2004 32.9 1 in 88 164.4 1 in 8
2005 33.5 1 in 86 166.6 1 in 8
2006 32.3 1 in 89 170.0 1 in 7
2007 31.0 1 in 104  Not available
Source: www.aihw.gov.au/cancer/index.cfm (cancer incidence and mortality 
data)
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The answer to the first question is simple: we are finding more 
cancers because there is more testing. The rising incidence of the 
disease does not mean that within a few years, there was somehow a 
sudden “spread” or rise of the disease – that many more Australian 
men were somehow acquiring prostate cancer. There is no claim 
being made by anyone that this has occurred, in the way for example 
we can easily demonstrate historical rises in the incidence of lung 
cancer as a time-lagged response to rising smoking rates 30 to 40 
years before. Instead, the rise can be readily explained by the spread 
of PSA testing and the related phenomenon of the rise of voices 
urging that men be screened for the disease. 
The second question – why there has been no significant change to 
the prostate cancer death rate in nearly 40 years – suggests that if the 
main argument in favour of finding all the previously undiagnosed 
prostate cancer is that this will reduce deaths from the disease, then 
this plainly has not happened. Further evidence relevant to this 
fundamental point is discussed on page 97 where we consider the 
results of two important randomised controlled trials of the PSA 
test, examining whether screening across a large number of men 
saves lives.
3What is the risk of being diagnosed with 
prostate cancer? 
Just as the risk of dying from prostate cancer increases as men age, so does the risk of being diagnosed with prostate cancer (i.e. its 
incidence). This is clear in Figure 2 below, which shows that prostate 
cancer is very rare in men under 40 but rises steadily with age from 
around the age of 40 to around the age of 70 when the incidence 
curve flattens out. 
Advancing age is the most important risk factor for death from nearly 
every disease. Except for certain illnesses of infancy and childhood, 
and road deaths (which peak in people in their 20s), nearly every 
cause of death is far more common in older than younger people. 
The same is very true for prostate cancer. In Table 2, we saw that the 
average age that men died from prostate cancer in Australian in 2007 
was 79.8, quite easily the oldest average age from death from any 
of the major causes of cancer death shown. All the other causes of 
cancer death kill men on average some seven to eleven years earlier. 
Table 5 shows both the number of men diagnosed in 2005 in each 
age group, and the age-specific rate of prostate cancer diagnosis per 
100,000 men in each age group.
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Of the 17,444 cases of prostate cancer diagnosed in 2006, just 329 
(1.9%) occurred in men aged less than 50. By contrast, 11,079 
(63.5%) were in men aged 65 and over. Adjusted for the number of 
men in each age band, Table 5 shows that the likelihood of a man 
aged 75–79 (where the odds are highest) being diagnosed as having 
prostate cancer in one year is one in 232, some 227 times more likely 
than a man aged 40–44, where the disease is uncommon, and 4274 
times more than a man aged 30–34, where the disease is extremely 
rare. The probabilities of any man aged less than 40 being diagnosed 
with prostate cancer are thus far lower than those of winning first 
prize in a lottery where 200,000 tickets are typically sold. These are 
astronomically low odds. The rate at which men aged 40–44 are 
being diagnosed with prostate cancer is one in 52,632 and from age 
45–49, one in 6,250 – still a very low risk.
Table 5: Number and rate of prostate cancer diagnoses, different age groups, 
Australia 2005. 
Age-group 
and number of 
prostate cancer 
diagnoses
Rate per 100,000 
men
Age-group 
and number of 
prostate cancer 
diagnoses
Rate per 100,000 
men
20–24: 1 0.1 (1 in 1 million) 55–59: 2037 164.5 (1 in 608)
25–29: 0 0 (–) 60–64: 2572 274.5 (1 in 364)
30–34: 1 0.1 (1 in 1 million) 65–69: 3141 412.0 (1 in 243)
35–39: 3 0.2 (1 in 500,000) 70–74: 2672 427.0 (1 in 234)
40–44: 29 1.9 (1 in 52,632) 75–79: 2372 431.9 (1 in 232)
45–49: 235 16.0 (1 in 6250) 80–84: 1474 372.5 (1 in 268)
50–54: 803 60.0 (1 in 1667) 85+: 988 323.8 (1 in 309)
Source: d01.aihw.gov.au/cognos/cgi-bin/ppdscgi.exe?DC=Q&E=/Cancer/
australia_age_specific_1982_2005
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Yet in 2010, the Prostate Cancer Foundation of Australia ran TV 
advertising featuring several Australian male sporting and acting 
celebrities in their 30s saying to camera that every year prostate 
cancer kills men “just like me”. As we saw in Table 2, in 2007 there 
were no cases of men “just like them” in their 30s who died of prostate 
cancer in Australia. Many young men seeing these advertisements 
with the rapid cavalcade of highly recognisable men in their 30s and 
40s, would assume that it was common for men of this age to die of 
prostate cancer. This is a highly misleading message.
The chance of having prostate cancer diagnosed depends not only 
on age but on the extent to which men voluntarily come forward 
to be tested to see if they have the disease. What we know is that 
the more we look for prostate cancer, the more we will find. So the 
lifetime odds of a man being diagnosed depend very strongly on the 
extent to which men come forward to be tested. If few come forward, 
far fewer will be diagnosed and so the probability of any man in the 
community getting a diagnosis will be lower. 
As we saw before, if a man was to conscientiously get PSA tested 
every year from (say) age 50, we know from autopsy studies that 
about 12% of men in their 40s, and around 40% of men in their 
70s [42] could be found to have the disease, if only we looked 
carefully enough for it. There is a huge reservoir of prostate cancer 
in the community that could be found if we test enough people, 
often enough. If those promoting testing are successful, many more 
men could be diagnosed with prostate cancer and thereafter have to 
live with this knowledge. Many would undergo traumatic surgical 
intervention which may profoundly affect their lives. But because 
the death rates from prostate cancer have barely changed in nearly 
40 years, what would have been the point in all this early disease 
finding?
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In 2009, the Urological Society of Australia called for all men in their 
40s (and over) to get themselves tested. So far, no group of urologists 
or prostate screening advocates have called for men under 40 to be 
screened, but by the same “finding a needle in a haystack” reasoning 
behind the call to screen 40–50-year olds, it may not be inconceivable 
that someone will reduce the recommended testing age even lower. 
By spreading concern and some anxiety to men in their 40s about 
the disease, a large number might get tested, to the obvious financial 
benefit of the diagnostic industries concerned. As we will see later 
in the book (see p81) such testing will result in a large number of 
men having their prostates surgically removed, and a significant 
proportion of these men having serious and lasting side effects of 
that surgery such as sexual impotence.
Why are we seeing increases in prostate cancer in Australia?
Today, after non-melanoma forms of skin cancer, prostate cancer 
is easily the most commonly diagnosed cancer in Australia. As 
can readily be seen in Table 6, since 1988 there have been a series 
of dramatic increases in the number of newly diagnosed cases of 
prostate cancer in Australia, most particularly between 1988 and 
1994, and 2002–2004. The 41% leap in cases between 1992 and 1993 
was unprecedented. On the surface, some people would be tempted 
to look at this data and assume there has been a growing epidemic of 
prostate cancer in Australia. 
However, Australia’s experience mirrors that of many countries 
where the incidence of prostate cancer diagnosis rose after the 
introduction and promotion of the Prostate Specific Antigen (PSA) 
test in 1987–88. No-one knowledgeable about cancer would argue 
that these rapid rising numbers means that the “actual” incidence 
of prostate cancer is rising: it is not like the growth of obesity in 
recent decades. There is not actually more prostate cancer in the 
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community. What the rises mean is simply that more men are being 
tested and because of this, more cancer is being found. 
Table 6: New cases of prostate cancer, Australia 1982–2005 (percentage change 
from previous year)
1982: 3680 1995: 12369 (–5.4)
1983: 3744 (+1.7) 1996: 10304 (–16.7)
1984: 3884 (+3.7) 1997: 9993 (–3.0)
1985: 4156 (+7) 1998: 10087 (+1.1)
1986: 4306 (+3.6) 1999: 10581 (+4.9)
1987: 4563 (+6) 2000: 10835 (+2.4)
1988: 4767 (+4.5) 2001: 11389 (+5.1)
1989: 5301 (+11.2) 2002: 12177 (+6.9)
1990: 6109 (+15.2) 2003: 13774 (+12.9)
1991: 6755 (+10.6) 2004: 15898 (+15.4)
1992: 7920 (+17.2) 2005: 16560 (+4.2)
1993: 11180 (+41.2) 2006: 17444 (+13.5)
1994: 13073 (+16.9)
Sources: d01.aihw.gov.au/cognos/cgi-bin/ppdscgi.exe?DC=Q&E=/Cancer/
australia_age_specific_1982_2005 and www.aihw.gov.au/cancer/data/acim_
books/index.cfm
What are Australian men told about prostate cancer in the 
media?
Prostate cancer has become a big health news story, being the third 
most reported cancer after breast cancer and melanoma [46]. Much 
of this reportage – although certainly not all – is accurate and 
important in raising awareness [47]. But overwhelmingly, it actively 
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promotes screening. As we saw at the beginning of this book, even 
though nearly all expert bodies which have reviewed the evidence 
on the ability of screening to save lives have concluded that the risks 
outweigh the benefits and that the number of lives saved because of 
screening would be small, this is decidedly not the message that is 
being communicated to men in the media [48]. 
In a study one of us (SC) published in 2007 on the accuracy of media 
reports about prostate cancer in 388 Australian newspaper and 42 
television items, one in ten statements reported to the public were 
found to be inaccurate [47]. Examples of these included:
Prostate cancer, which kills more men in this country than 
any other form of the disease 
Prostate cancer is … the biggest cause of cancer death 
in males … treat men for their commonest lethal cancer 
[wrong! Lung cancer kills far more] 
Prostate cancer is the second biggest killer of Australian 
men [wrong! Heart disease, lung cancer, stroke and chronic 
obstructive pulmonary disease kill more men].
As we finished writing this book in August 2010, the Prostate Cancer 
Foundation of Australia’s website [49] states, “Each year in Australia, 
close to 3,300 men die of prostate cancer – equal to the number of 
women who die from breast cancer annually.” In fact, there has never 
been a year in which “close to 3,300” men died of prostate cancer in 
Australia. The highest number that has ever occurred in one year 
was in 2005, when 2950 men died from the disease. In 2008, the 
Australian Institute of Health and Welfare (AIHW) published a 
projection for the number of prostate cancer deaths in Australia of 
3366 in 2010 [50]. In the same report, it projected the figure of 3124 
deaths from the disease in 2007. But in fact, as we saw in Table 1, 
2938 men died from the disease in 2007 (the latest year for which 
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data is available) – some 6% less than projected. The “3,330 each 
year” figure is therefore nearly 13% higher than the highest number 
ever recorded. 
The Foundation’s chief executive, Andrew Giles, was reported in The 
Sydney Morning Herald in July 2010 as claiming that prostate cancer 
would soon become the No. 1 killer of Australian men: 
By about 2015 the number of men this disease is killing is 
going to exceed the number of men who die of lung cancer, 
because that tumour is coming down thanks to all the work 
we do in tobacco control. So prostate cancer will be the 
number one killer of men. [51]
So how credible is this claim? In December 2008, AIHW estimated 
that in 2010 there would be 4687 deaths from lung cancer and 
3366 deaths from prostate cancer [50]. In fact, in 2007 – the latest 
available year, there were 4715 lung cancer deaths and 2938 deaths 
from prostate cancer. Far from going down, lung cancer deaths 
averaged 4675 across the seven years (2001–07). In the three years 
between 2007 and 2010, the AIHW estimated that deaths from 
prostate cancer would grow by 428, or an average of 143 deaths a 
year. If this continued until 2015, this would mean that in the seven 
years (2007–2015), an extra 1000 deaths per year might occur, 
giving a rough total of 3939. If total lung cancer deaths continue to 
plateau as they have between 2006 and 2010, this would mean that 
Mr Giles’ prediction would fall some 746 deaths short – about a 25% 
overestimate.
In 2007, Professor John Shine, head of Sydney’s Garvan Institute, 
sent a fundraising letter to thousands of potential donors. It stated, 
“every single hour at least one man dies of prostate cancer”. Author 
(SC) wrote to the Garvan pointing out that this statement was 
massively incorrect. If prostate cancer killed one man an hour there 
47
would be 8760 deaths from the disease each year in Australia. With 
2952 deaths in 2006, they overstated the true figure by 5808 – nearly 
300% – explained later as an error arising from an extrapolation 
from UK data, unadjusted from that nation’s far greater population. 
On 5 June 2007, Dr Andrew Rochford from Channel 7’s What’s Good 
for You stated that “prostate cancer is second only to heart disease” in 
killing Australian men. Prostate cancer is not “second only to heart 
disease” as a cause of death either. Prostate cancer was in fact the 
sixth leading cause of death in men, a very long way behind ischemic 
heart disease which kills 13,152 men a year; stroke (4826); lung 
cancer (4733); other heart disease (3290); and chronic obstructive 
pulmonary disease (2986). Further, ischemic heart disease causes 
much more disability in the community than prostate cancer. 
Ischemic heart disease causes the loss of 151,107 DALYs (Disability 
Adjusted Life Years), compared with 36,546 lost to prostate cancer, 
putting it in ninth place by that criterion.
In August 2010, the Prostate Cancer Foundation issued press releases 
to publicise a conference it was hosting in Queensland. One report 
stated “the National Cancer Institute in the USA has in the last 
month reversed previous opposition to PSA tests and thrown out 
previous contrary studies”. We wrote to the NCI to ask whether this 
statement was accurate. They replied saying “Please note that as a 
Federal research agency, the NCI does not set screening guidelines”. 
They also referred us to the website of the Agency for Healthcare 
Research and Quality (AHRQ) which they said 
is the Federal agency responsible for setting screening 
guidelines. You may wish to explore the U.S. Preventive 
Services Task Force (USPSTF) “Screening for Prostate 
Cancer: Recommendation Statement.” 
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The USPSTF, which is sponsored by the AHRQ, is an independent pan-
el of experts in primary care and prevention that rigorously evaluates 
clinical research in order to assess the merits of preventive measures, 
including screening tests. The link provided (www.uspreventiveser-
vicestaskforce.org/uspstf/uspsprca.htm) states unequivocally:
The USPSTF concludes that the current evidence is 
insufficient to assess the balance of benefits and harms 
of prostate cancer screening in men younger than age 75 
years.
The USPSTF recommends against screening for prostate 
cancer in men age 75 years or older.
In other words, the idea that the NCI was ever “opposed” to prostate 
screening is misleading, as is the idea that the NCI has now “reversed” 
such opposition.
These examples are a small taste of some of the misinformation that 
is circulating about prostate cancer. 
4What increases or decreases the risk  
of prostate cancer? 
Does prostate cancer “run in families”? If you have relatives who have had prostate cancer, are your chances higher of getting the 
disease?
Increasing age is the strongest predictor of a diagnosis of prostate 
cancer, but the second most important predictor is family history. 
Around 10–20% of men with prostate cancer have a family history of 
the disease (meaning that 80–90% don’t) [52]. Given what we have 
summarised earlier about many men dying with rather than from 
prostate cancer, and never knowing that they had the disease, it is 
possible that part of this apparent excess rate in men with a family 
history may be due to their higher participation in testing. We know 
of no studies that have considered this possibility. Men who have a 
first degree relative (a father or brother) who has had prostate cancer 
are twice as likely to be diagnosed with prostate cancer as men with 
no affected relative [53]. The risk increases with the increasing 
number of affected relatives and with decreasing age at the diagnosis 
of those with the disease. Men with family history of prostate cancer 
typically have the disease diagnosed six to seven years earlier than 
men without a family history [52]. This can often be due to increased 
concern about the disease in such men and their willingness to be 
regularly tested [54].
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The most recent and largest meta-analysis on family history and 
prostate cancer (a meta-analysis is a study which combines all pub-
lished high quality studies about a topic to assess what they all say 
when combined together) found the following increased risks [55]. 
In summary, cancer risk increases with:
1. Earlier onset of the disease in other family members
2. Increased total number of affected relatives in the family
3. Increased number of first degree relatives affected by the dis-
ease. [54]
Table 7: Family history and the probability of prostate cancer diagnosis
Relatives with prostate cancer Relative risk (95% confidence interval)
One First degree relative (FDR) 2.57 (2.32–2.84)
Brother only 3.37 (2.07–3.83)
Father only 2.17 (1.90–2.49)
Two or more FDRs 5.08 (3.31–7.79)
One FDR diagnosed younger than 65 
years
2.47 (1.71–3.55)
One FDR diagnosed older than 65 
years
1.72 (1.41–2.10)
Note: A relative risk (RR) of 1 means that there would be no difference for the 
probability of a prostate cancer diagnosis between a man with a family history 
of the disease and a man with no such history. A RR of 2.57 thus means that a 
man with the family history has 2.57 times the likelihood of such a diagnosis 
compared to a man with no such history.
Unfortunately, a reliable genetic test that can discriminate between 
men at risk and not at risk is currently unavailable [56].
The 2010 Prostate Cancer Foundation advertising campaign gave 
this message to men: all men over 50 should consult their doctor 
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about being tested, and that all men between 40 and 50 with a “fam-
ily history” of the disease should also consult their doctor. As we saw 
earlier, the great majority of prostate cancer diagnoses and deaths 
occur in older men. It follows from this that the great majority of 
men with a relative with a family history will have had those relatives 
diagnosed and/or die with prostate cancer late in life.
As stated above, the risk of being diagnosed with prostate cancer is 
increased by a factor of about two to three if your father had prostate 
cancer. For a man in his early 40s, this increases his risk of being diag-
nosed with prostate cancer from about one in 52,000 to about one in 
17,000 to 26,000; for a man in his early 50s, it would increase the risk 
from about one in 1600 to about one in 500 to 800 (see Table 5). 
Some who advocate PSA screening in younger men argue that 
prostate cancer is more aggressive when it is diagnosed in young-
er men. Recent, detailed studies have had conflicting results, some 
suggesting that prostate cancer diagnosed in younger men is more 
aggressive than average, others suggesting it is less aggressive [57, 
58]. The outcomes of prostate cancer treatment in younger men are 
probably as good or better than those in older men. However, there 
is no doubt that men diagnosed with prostate cancer at a younger 
age have more at stake: their average life expectancy without prostate 
cancer is longer; left untreated, the prostate cancer has more time to 
cause further problems; if treated, the prostate cancer has more time 
to recur.
Can anything be done to prevent prostate cancer?
With some cancers, we know that avoidance of particular exposures 
(ultra-violet radiation from sunlight and solaria, radiation, smoking, 
asbestos, soil radon, certain industrial chemicals) can do much 
to reduce the risk of getting cancer. So what is the situation with 
preventing prostate cancer?
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Diet
Dietary factors are associated with both the promotion and 
protection of many diseases and health-related conditions: some 
types of diet promote some cancers and others appear to protect 
against some cancers [59]. Different diets are associated with both a 
higher and lower prevalence of various diseases and there is growing 
community understanding of this broad principle. Indeed, in a recent 
study, 73% of Australian men who had a family history of prostate 
cancer believed that diet was a factor associated with prostate cancer 
[60]. So are there in fact diets which appear to be associated with a 
lower population incidence of prostate cancer? 
If you search Google for “diet and prostate cancer” you will get 
2,240,000 hits. The great majority of these are entrepreneurial 
complementary (alternative) medicine sites promoting and selling 
a large range of dietary supplements, most of which will probably 
do little but generate expensive urine for you. There is unfortunately 
little accepted scientific evidence that dietary modification (reducing 
or increasing the intake of certain foods or elements) is a reliable 
way of reducing the risk of acquiring prostate cancer. Below we 
summarise some of the more important systematic reviews and large 
trials in the accumulated evidence about whether this disease can be 
prevented.
Overall diet
A recently published report from Victoria, a multicultural state 
where one can find a diversity of diets, followed 14,627 men aged 34 
to 75 years for an average of 13.6 years, and identified 1018 cases of 
prostate cancer in the study group. The study “found no association 
between any dietary pattern and prostate cancer risk overall” nor did 
it find any association with cancer aggressiveness, Gleason score (see 
p67) or age at diagnosis [61].
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Green tea
Daily consumption of green tea has long been thought to have 
a protective effect on cancer. A July 2009 Cochrane review of the 
role of green tea consumption in reducing the incidence of cancer 
(including prostate cancer) involved 51 studies with more than 1.6 
million participants. The review concluded that 
The evidence that the consumption of green tea might reduce 
the risk of cancer was conflicting. This means that drinking 
green tea remains unproven in cancer prevention, but appears 
to be safe at moderate, regular and habitual use. [62]
Lycopene (tomatoes)
In the US in particular, it has become common for men to try to 
regularly eat tomatoes because of beliefs that their high content of 
lycopene – an anti-oxidant – may protect against prostate cancer. An 
analysis of 19 published studies on this subject concluded 
our results show that tomato products may play a role in 
the prevention of prostate cancer. However, this effect is 
modest. Despite the preventive benefits of lycopene found 
in this study, the existing evidence is not overwhelming 
enough to recommend the use of lycopene supplements in 
the prevention of prostate cancer. 
The only benefit – which was statistically small – was seen in those 
who ate high amounts of tomato [63]. 
Selenium and vitamin E
A large double-blinded trial of either and both selenium and vitamin 
E undertaken among 35,533 men recruited in 427 North American 
sites where the median follow-up period was 5.46 years showed that 
selenium (a trace mineral) or vitamin E, alone or in combination did 
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not prevent prostate cancer in this population of relatively healthy 
men compared with placebo [64].
Chemoprevention (finasteride)
Finasteride is a drug which inhibits the action of 5a-reductase, the 
enzyme that converts testosterone to the more potent androgen 
dihydrotestosterone. It is used to treat benign prostatic hyperplasia 
or BPH (see p22) and is also used by millions of men around the 
world to control baldness. The development of finasteride also 
allowed the possibility of studies being conducted to see if lowering 
androgen levels in the prostate would reduce the risk of prostate 
cancer. The Prostate Cancer Prevention Trial [65] set out to test this 
hypothesis. It involved allocating 
18,882 men aged 55 years and over who had normal digital 
rectal examinations and a PSA level of 3.0 ng per millilitre 
or lower to treatment with finasteride (5 mg per day) or 
placebo for seven years. Prostate biopsy was recommended if 
during the trial, the annual PSA level, adjusted for the effect 
of finasteride, exceeded 4.0 ng per millilitre or if the digital 
rectal examination was abnormal.
The study directors calculated that 
60 per cent of participants would have prostate cancer 
diagnosed during the study or would undergo biopsy at the 
end of the study and the main outcome of interest was the 
prevalence of prostate cancer during the seven years of the 
study.
The study demonstrated that by taking this drug every day for seven 
years, 18.4% of the men on finasteride developed prostate cancer 
compared with 24.4% of men on the placebo, a relative reduction of 
24.8% in prevalence over the seven-year period. 
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However, adverse sexual side effects were more common in the 
finasteride-treated men: reduced ejaculatory volume 60.4% in finas-
teride group vs 47.3% in control group; erectile dysfunction (67.4% 
vs 61.5%); loss of libido (65.4% vs 59.6%); gynecomastia (develop-
ing “man boobs”, 4.5% vs 2.8%). In addition, aggressive tumours of 
Gleason grade 7, 8, 9, or 10 were more common in the finasteride 
group (37%) than in the placebo group (22.2%). The study authors 
concluded that the drug 
prevents or delays the appearance of prostate cancer, but this 
possible benefit ... must be weighed against sexual side effects 
and the increased risk of high-grade prostate cancer.
By saying it “prevents”, they of course do not mean that it prevents 
the disease in all men taking it, but that it reduces the incidence of the 
disease. And the absolute size of this reduction was only 6% – 24.4% 
of men not taking the drug for seven years were diagnosed with 
prostate cancer, while 18.4% of the men on finasteride developed 
prostate cancer. Moreover and very tellingly, 
there was no significant difference in the number of deaths 
between the two groups: five men in each group died from 
prostate cancer.
Subsequently, further analyses of this trial have suggested that there 
may not have been an increased risk of more aggressive cancers in 
the finasteride group after all [66, 67]. It is possible that this appar-
ent increase was caused by biases in reporting the results of biopsies 
among men in the finasteride group. Analyses adjusting for this bias 
found little or no increased risk of high grade cancer with finasteride; 
in fact finasteride may even reduce the risk of developing aggressive 
prostate cancer, just as it appears to reduce the risk of prostate cancer 
overall. 
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So to summarise, we have good evidence that finasteride produces 
a modest reduction in prostate cancer with long term use. But those 
taking it have elevated levels of sexual problems. That information 
should be entered into men’s calculations when deciding whether 
to take it. 
Ejaculatory frequency
Because the prostate is a sexual organ which supplies fluid to the 
ejaculate, it is understandable that researchers have considered the 
possibility that frequency of ejaculation (high, low, and at what stages 
in life) might have something to do with prostate cancer. Studies 
have produced mixed findings. A large cohort study of 29,342 US 
health professional men found that 
Most categories of ejaculation frequency were unrelated to 
risk of prostate cancer. However, high ejaculation frequency 
was related to decreased risk of total prostate cancer.
Averaged across their lifetime, men who reported 21 or more 
ejaculations per month compared with men reporting four to seven 
ejaculations per month had a reduced relative risk of prostate cancer 
of 0.67 (95% CI, 0.51–0.89) – in other words, a 33% reduced risk. 
Other than for this high frequency category of ejaculation, the 
authors concluded, “Our results suggest that ejaculation frequency 
is not related to increased risk of prostate cancer” [68]. However, 
a more recent study showed that men who engaged in frequent 
masturbation, of about two to seven times a week, during their 20s 
and 30s, had a higher rate of prostate cancer, while men who engaged 
in masturbation once a week during their 50s had a lower rate [69].
These studies do not really provide men with much confidence to 
embark on a changed ejaculatory regimen, justifying it with hopes 
of preventing prostate cancer. 
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Physical activity
A 2001 review of the published literature on whether being 
physically active might protect against prostate cancer found 
that the “epidemiologic data supporting this hypothesis are weak 
and inconsistent” [70]. But of course physical activity is to be 
recommended for its many other important health promoting 
effects, including the prevention of other types of cancer.
5How is prostate cancer diagnosed?
The Prostate Specific Antigen (PSA) test first became available in 1987 and began to be widely used and promoted thereafter. 
The test is done by obtaining a blood sample which is then sent to 
a pathology laboratory for analysis. The test measures the level of 
Prostate Specific Antigen in the blood. Prostate Specific Antigen is 
a protein made mainly in the prostate gland and low levels of PSA 
are normally present in the blood. As a man ages, the prostate grows 
and the level of PSA also increases. A high PSA in the blood almost 
always means that something is wrong with the prostate, but not 
necessarily that it is prostate cancer. The causes of a high PSA include 
the benign (non-cancerous) growth that accompanies ageing (benign 
prostatic hyperplasia, BPH) (see p22), inflammation or infection of 
the prostate (prostatitis) (see p21) and, least commonly, prostate 
cancer. 
What is the range of PSA levels?
PSA results are returned from the pathology lab expressed as 
nanograms of PSA per millilitre (ng/mL) of blood. Your PSA test 
will produce a number and your doctor should try to explain the 
meaning of that number to you. However this isn’t easy because the 
PSA test is not an accurate test for detecting prostate cancer and 
understanding what your number means is far from straightforward. 
It has been conventional to regard a PSA level of 4 ng/ml or higher as 
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“abnormal”, and values less than 4 ng/ml as “normal”. Results over 4 
ng/ml are likely to lead to a recommendation to have a biopsy of the 
prostate to see why the PSA level is “raised”. However, as described 
above, there are many reasons why PSA levels can rise, without any 
cancer being present. In fact most men with PSA levels of 4 ng/ml 
or more don’t have prostate cancer. In several studies, about 30% 
of men with PSA levels of 4 ng/ml or higher were found to have 
prostate cancer, meaning of course that the other 70% did not have 
cancer [71]. 
To complicate things further, having a PSA level less than 4 ng/ml 
does not mean a man does not have prostate cancer. In one large US 
study, prostate cancer was diagnosed in 15% of men with PSA less 
than 4 ng/ml [72]. Because of this, there has been a trend toward 
dropping the threshold for an “abnormal” PSA test result. In the 
large European Randomized Study of Screening for Prostate Cancer 
(more on this study later) the threshold for “abnormal” was dropped 
from 4 ng/ml to 3 ng/ml. Other experts have suggested different 
thresholds for “abnormal” according to age, because PSA levels tend 
to rise with age. According to this approach, a PSA level of up to 2.5 
ng/ml is considered normal for a man in his 40s, but a PSA level of 
up to 6.5 ng/ml is considered normal for a man in his 70s (see Table 
8). However there is no evidence to date that these age-adjusted 
thresholds result in better health outcomes, and there is still no 
consensus about which threshold(s) should be used to call a result 
abnormal. For example in 2009, the Urological Society of Australia 
and New Zealand proposed PSA testing for men from the age of 40 
and suggested a PSA level of 0.6 ng/ml be considered “higher risk” 
for a man aged 40 and a PSA of 0.7 ng/ml be considered “higher 
risk” for a man aged 50. 
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Table 8: Upper limits of “normal” for PSA at different age groups (ng/ml)
Age range Upper limit of normal
40–49 2.5 
50–59 3.5 
60–69 4.5 
70–79 6.5 
Source: [73]
While using lower thresholds for an “abnormal” or “higher risk” 
result has the advantage of detecting more prostate cancers, there 
are two problems with this approach. The first is that, as we’ve seen, 
there is a big reservoir of indolent prostate cancer and there is no 
evidence that finding all these cancers will be beneficial or result in 
fewer deaths from prostate cancer. The second is that by dropping 
the threshold, many more men get caught up in the medical net 
of “abnormal” or “higher risk” and then have more tests including 
prostate biopsies. For example, in a community sample of men 
having PSA tests, using a threshold of 3.5 instead of 4 ng/ml for 
men aged 50–59 years, twice as many men (4% vs 2%) received an 
“abnormal” result. Dropping the threshold to 0.7 ng/ml could result 
in approximately half of all men in this age group receiving a “high 
risk” result, and being sent for more blood tests and/or biopsies with 
all the inconvenience, anxiety, risks and costs involved in these extra 
tests. 
In summary, there is no agreement about what constitutes a normal 
or abnormal PSA level: there is no “threshold” PSA score from 
which you can conclude that you are or are not highly likely to 
have prostate cancer. The above studies demonstrate that the PSA 
test has both poor “sensitivity” (ability to detect cancer if it’s there) 
and poor “specificity” (ability to give a true negative), leading to 
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many false alarms or false positive results. All this means that many 
men are unnecessarily subjected to prostate biopsies because of the 
imprecision of the test. And a prostate biopsy is by no means a trivial 
and risk-free procedure (see p62). Perhaps the only clear thing we 
can say is that in general, the higher a man’s PSA level, the more 
likely it is that cancer is present. 
Dr Richard Ablin, the scientist who discovered the Prostate Specific 
Antigen in 1970, wrote forcefully about it in March 2010 in The New 
York Times, describing the test’s popularity as “a hugely expensive 
public health disaster”. He continued 
the test is hardly more effective than a coin toss. As I’ve 
been trying to make clear for many years now, P.S.A. testing 
can’t detect prostate cancer and, more important, it can’t 
distinguish between the two types of prostate cancer — the 
one that will kill you and the one that won’t.
Ablin pulled no punches. 
So why is it still used? Because drug companies continue 
peddling the tests and advocacy groups push ‘prostate cancer 
awareness’ by encouraging men to get screened. Shamefully, 
the American Urological Association still recommends 
screening ... Testing should absolutely not be deployed 
to screen the entire population of men over the age of 50, 
the outcome pushed by those who stand to profit. I never 
dreamed that my discovery four decades ago would lead 
to such a profit-driven public health disaster. The medical 
community must confront reality and stop the inappropriate 
use of P.S.A. screening. Doing so would save billions of dollars 
and rescue millions of men from unnecessary, debilitating 
treatments. [74]
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What happens if you have a high PSA score?
A high PSA score causes concern (and as we have seen, what is 
meant “high” is by no means clear – it can be in fact as low as 2.5, 
according to some [73]). But if your doctor interprets your PSA as 
“high” then two options are available. The first is known as early 
stage “active surveillance” or “expectant management”. Basically, 
active surveillance at this stage will involve urging you to have 
more regular PSA tests and probably digital rectal examinations to 
monitor your prostate.
But the second option is to refer you for a biopsy [75]. 
What happens when you have biopsy for prostate cancer? 
A biopsy involves the extraction of body tissue via a needle so that 
the tissue can be then examined by a pathologist. The prostate is 
biopsied through the rectum and the procedure usually takes 10 to 15 
minutes. The procedure is performed by a urologist. An ultrasound 
device is used to view the prostate on a monitor and guide the biopsy 
needles. A lubricated ultrasound sensor is passed into the rectum. 
For some this is uncomfortable, but not usually painful. 
The biopsy needles are introduced through the shaft of the ultrasound 
sensor. The needles are then pushed through the rectal wall into the 
adjacent prostate gland. The needles collect at least 12 samples of 
prostate tissue which are then sent to a pathologist for testing. A 
sharp stinging sensation is sometimes experienced. Occasionally the 
biopsy is not successfully completed and may need to be repeated.
Common side effects of prostate biopsy include:
•	 pain or discomfort in the rectal area
•	 distress caused by the sound of the biopsy gun
•	 anxiety about the biopsy and its results 
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•	 blood-stained urine or faeces – this can last up to a week or two. 
One large Dutch study found blood-stained urine in 23.6% of 
men [76] 
•	 blood-stained or discoloured semen – this may last for six 
weeks. The same large study found 45.3% of men had blood in 
their semen
•	 difficulty in passing urine – this usually improves quickly. 
More serious complications can also arise, although less often. These 
can include urinary or bowel infection, and far more uncommonly, 
massive life-threatening rectal bleeding [77], septicaemia (infection 
of the bloodstream) and even death [78]. In the large Dutch study 
referred to above, 0.4% (67) of 1687 men who had undergone 
biopsy had complications serious enough to be admitted to hospital 
following the procedure. The biopsy needles have to pierce the rectal 
wall to get to the prostate and bacteria from the bowel may cause 
an infection. A dose of antibiotic is often given to reduce the risk of 
infection. 
What are the downsides to being told “you have cancer”? 
The first consequence of being told that you have cancer in your body 
is that you henceforth will think of yourself as a man who has cancer. 
This may seem so obvious as to be hardly worth mentioning, but it 
bears careful reflection. Knowing that one has cancer can often be an 
emotionally traumatic experience which can preoccupy some men, 
causing anxiety and particularly prolonged and repeated periods of 
depression [6]. 
But as we have been saying throughout the book, the prostate cancer 
that you have stands a high chance of being a cancer that may never 
harm you. 
As well, the knowledge that you now have cancer may impact on lives 
in subtle ways. For example knowing you have prostate cancer may 
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affect your health insurance or life insurance. It can also reverberate 
around families because it means everyone else now has a relative 
affected by prostate cancer. That knowledge in turn affects the way 
doctors and insurance companies will perceive your male relatives 
as being at higher risk of prostate cancer. 
A recent study from Sweden adds important evidence to the debate 
that getting a prostate cancer diagnosis can increase your risk of 
having a cardiovascular event or taking your own life. The editors 
of the highly regarded medical research journal which published the 
study (PLoS Medicine) summarised the study this way: 
The researchers identified nearly 170,000 men diagnosed 
with prostate cancer between 1961 and 2004 among Swedish 
men aged 30 years or older by searching the Swedish Cancer 
Register. They obtained information on subsequent fatal and 
nonfatal cardiovascular events and suicides from the Causes 
of Death Register and the Inpatient Register (in Sweden, 
everyone has a unique national registration number that 
facilitates searches of different health-related Registers). 
Before 1987, men with prostate cancer were about 11 times 
as likely to have a fatal cardiovascular event during the first 
week after their diagnosis as men without prostate cancer; 
during the first year after their diagnosis, men with prostate 
cancer were nearly twice as likely to have a cardiovascular 
event as men without prostate cancer (a relative risk of 1.9). 
From 1987, the relative risk of combined fatal and nonfatal 
cardiovascular events associated with a diagnosis of prostate 
cancer was 2.8 during the first week and 1.3 during the first 
year after diagnosis. The relative risk of suicide associated 
with a diagnosis of prostate cancer was 8.4 during the first 
week and 2.6 during the first year after diagnosis throughout 
the study period. [This means that compared with men 
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not diagnosed with prostate cancer, men given a diagnosis 
were 8.4 times more likely to commit suicide in the week 
after being given the news, and 2.6 times more likely in the 
year after diagnosis.] Finally, men younger than 54 years at 
diagnosis had higher relative risks of both cardiovascular 
events and suicide.
These findings suggest that men newly diagnosed with 
prostate cancer have an increased risk of cardiovascular events 
and suicide ... these findings strongly suggest that the stress 
of the diagnosis itself rather than any subsequent treatment 
has deleterious effects on the health of men receiving a 
diagnosis of prostate cancer ... this new information should 
be considered in the ongoing debate about the risks and 
benefits of PSA screening. [79] 
However, another very recent Swedish study which compared men 
who had had prostate cancer detected after a PSA test with age-
matched men without prostate cancer in the general population and 
also with men with advanced or metastatic prostate cancer found 
that there was no increased risk of suicide in the newly diagnosed 
men, whereas the risk was twice as high among men with locally ad-
vanced or metastatic disease, compared with the age-matched male 
population [80].
What do stage, grade and Gleason score mean? 
Prostate cancers are often described by their stage, grade, or Gleason 
score [81]. 
A cancer’s stage refers to its extent at diagnosis, in other words, the 
parts affected by the cancer when it first became evident. Staging is 
important to both estimating prognosis and selecting treatment. The 
most common staging system is the TNM system which summarises 
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the extent of the primary tumour (T), spread to local lymph nodes 
(N), and spread to other parts of the body (M) by assigning numbers 
to each of these letters.
The most important distinction in staging a prostate cancer is 
whether or not it appears confined to the prostate. In T1 and T2 
cancers, the primary tumour is confined to the prostate, whereas 
in T3 and T4 cancers, the primary tumour has grown beyond the 
prostate into adjacent tissues. T1 and T2 cancers are often referred 
to as “early stage cancers” and have the best outlook, with or without 
treatment. T3 and T4 are more serious and are often referred to as 
“locally advanced cancers”. N1 cancers have evidence of spread to 
local lymph nodes, N0 cancers do not. M1 cancers have evidence of 
spread to other parts of the body, M0 cancers do not. Prostate cancers 
that have spread to local lymph nodes or beyond are incurable and 
are referred to as metastatic cancers.
There are several ways of determining evidence of spread beyond the 
prostate. These include computed tomography (CT or CAT) scans 
or magnetic resonance imaging (MRI) scans to assess spread within 
the pelvic region, and radio-isotope bone scans to assess spread into 
bones. These scans are often called staging tests. 
The problem with staging tests is that they are not 100% reliable. The 
main limitation is that no test is sensitive enough to detect cancer 
spread at its earliest stages, so a normal result does not rule out the 
possibility of cancer spread. So while these tests and staging are a 
helpful guide, they are not conclusive.
Cancers that appear confined to the prostate (T1–2 and N0 and 
M0) are potentially curable, whereas those that have spread beyond 
the prostate and its related lymph nodes (M1) are not curable with 
current treatments. Many prostate cancers involve adjacent tissues 
(T3–4) or related lymph nodes (N1) at diagnosis; these locally 
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advanced cancers are amenable to treatment, but their curability is 
controversial.
A cancer’s grade refers to how aggressive its cells look under a 
microscope. The Gleason score is the standard way of classifying 
a prostate cancer’s grade. It is named after Dr Donald Gleason, a 
pathologist at the Minneapolis Veterans Affairs Hospital who 
developed it with other colleagues in the 1960s. The Gleason score 
reflects how different the tumour looks from normal prostate tissue 
and suggests how aggressively it is likely to behave. 
To calculate the Gleason score for a prostate cancer, the pathologist 
looks at all available specimens and assigns a score from 1 (least 
aggressive looking, or low grade) to 5 (most aggressive looking or 
high grade) to the most common pattern and second most common 
pattern they see. Adding these numbers together gives the cancer’s 
Gleason score from a minimum of 2 (1+1 = least aggressive, lowest 
grade) to a maximum of 10 (5+5 = most aggressive, highest grade). 
In practice, it is unusual for pathologists to report a Gleason score of 
less than 4 (2+2). Most cancers have Gleason scores between 5 and 
10.
A lower Gleason score (5 or less) suggests that the cancer is growing 
slower, less likely to spread beyond the prostate, and therefore 
behaving less aggressively. Such cancers are often referred to as 
“low grade”. A higher Gleason score (8 to 10) suggests that the 
cancer is growing faster, more likely to spread beyond the prostate, 
and therefore behaving more aggressively. Such cancers are often 
referred to as “high grade”. Most men with prostate cancer have a 
Gleason score in the middle (6 or 7). These cancers are often referred 
to as “intermediate grade”.
Surviving prostate cancer is more likely with lower Gleason scores 
(see charts below). This is true with any prostate cancer treatment 
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or watchful waiting. In the charts, “age” means the man’s age when 
the cancer was found. The men in this research study used watchful 
waiting or hormone treatment. It should also be kept in mind that 
most men who survived prostate cancer died of other causes.
Tumours with higher Gleason scores (8 to 10) are described as 
aggressive. They are likely to grow and spread beyond the prostate 
within five years. Men with higher Gleason score prostate cancers 
therefore have potentially more to gain from active treatment. 
However, prostate cancers with higher Gleason scores are also more 
likely to have spread beyond the prostate and are therefore more 
difficult to cure.
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Source: www.effectivehealthcare.ahrq.gov/repFiles/ProstateCancerConsumer.pdf
 
6What are the treatments for early stage 
prostate cancer?
If a prostate biopsy and staging tests reveal an early stage cancer, then a number of options are available to you. The first is active 
surveillance or “watchful waiting”. This is an option frequently 
offered to men with tumours which have a low Gleason score (e.g. 
5 or 6). These cancers are often slow growing, and may never cause 
you harm. If you opt for watchful waiting, this basically means that 
for the time being, you and your doctor agree that you will have 
no treatment but instead, you will undergo regular check-ups 
(PSA, digital rectal examination, and probably further biopsies). 
Your doctor will thus know if there is evidence that the cancer is 
progressing and the risk of spread and further problems is increasing 
and warrants prostatectomy or radiation.
If you and your doctor decide to treat the cancer, then there are three 
main options: surgery to remove the cancer; radiation to eradicate 
the cancer; and hormonal treatment to try to get the cancer under 
control. Sometimes radiation and hormonal therapy are given in 
combination. Your doctor may recommend you have hormonal 
therapy before, during and/or after radiotherapy.
Radical prostatectomy is the complete surgical removal of your 
prostate. It will only be of potential benefit to men who have early 
stage prostate cancer which has not spread beyond the prostate. 
If your cancer has spread (metastasised) beyond the prostate and 
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surrounding tissues, then surgery is unable to eradicate the cancer 
on its own. A radical prostatectomy is not a minor operation. It is 
conducted under general anaesthetic. General anaesthetics have 
their own risks. A radical prostatectomy can be performed “open” 
through one large incision (5–10 cm), or “laparoscopically”, using 
instruments passed through several smaller incisions. 
Retropubic prostatectomy (open) is the most common procedure 
in Australia. Here, an incision of 8–10 cm is made between the 
navel and pubic bone through which the prostate and surrounding 
pelvic lymph nodes are removed. An open retropubic prostatectomy 
generally takes two and a half to three hours if nerves are not 
spared and three and a half to four hours if nerves are spared (see 
below). Removing the prostate means that the part of the urethra 
travelling through the prostate gland is also removed. The two ends 
of remaining urethra are then reattached in a connection called an 
anastomosis.
Perineal prostatectomy is an older open approach, where the 
prostate is removed through a 5 cm incision in the perineum – the 
skin and muscles between the scrotum and anus. 
Nerve-sparing surgery is designed (as the name implies) to 
minimise the number of nerves adjacent to the prostate that are 
damaged during the operation. Bundles of nerves on either side of 
the prostate are responsible for erections and can be either removed 
or damaged by surgery. If they remain undamaged, men may have 
a higher chance of regaining erections after surgery, typically within 
two to 12 months.
Some may ask why all prostatectomies are not nerve sparing? Surely, 
good surgeons would always seek to minimise damage to nerves? 
The problem is that these nerves are small, difficult to identify, 
fragile, and run along the outer surface of the prostate. Attempts to 
spare these nerves increase the risk that some prostate cancer will 
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be left behind, particularly if the cancer extends close to where the 
nerves pass.
Laparoscopic prostatectomy is a newer approach using a thin, 
tube-like instrument (laparoscope) which allows the surgeon to see 
inside the abdominal cavity and remove the prostate with other long 
thin instruments inserted through a series of small incisions. This 
operation is more demanding for surgeons than open prostatectomy 
because of the difficulty working through smaller incisions. Recovery 
times may be quicker because the incisions are smaller, however the 
operation often takes longer than an open prostatectomy and the 
risk of cancer recurrence may be higher.
Robotic prostatectomy is an even more recent surgical option that 
has received a lot of publicity. This involves the urologist using a 
machine to perform a laparoscopic prostatectomy. The surgeon 
operates instruments with a console rather than directly. Because it 
has received so much attention, we deal with this option in greater 
detail below at page 84.
A highly detailed account of what is involved in radical prostatectomy, 
including descriptions of problems that can arise can be found 
on Cornell University’s Department of Urology website (www.
cornellurology.com/prostate/treatments/prostatectomy.shtml).
Radiotherapy is a potentially curative treatment option when cancer 
has not spread beyond the prostate. Radiotherapy can also be used to 
treat symptoms caused by cancer cells that have spread to other parts 
of the body (metastasised). 
External beam radiation therapy (EBRT) is an external radiation 
therapy used in the treatment of prostate cancer. It is administered 
by a radiation oncologist after carefully mapping the prostate gland. 
For early prostate cancer, a typical course of treatment would see you 
have daily sessions (with weekends off) for four to seven weeks. Each 
session lasts a few minutes and is painless. 
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There are two main types of externally delivered radiotherapy: 
conformal, and IMRT (Intensity-Modulated Radiotherapy). With 
conformal radiotherapy, the radiotherapy device contours the 
radiation beams to match the prostate’s shape. This seeks to reduce 
the radiation received by healthy cells in adjacent organs such 
as the bladder and rectum, therefore reducing the side effects of 
radiotherapy.
IMRT is a newer, more complex type of conformal radiotherapy 
and allows the radiotherapist to vary the dose of radiation given to 
different parts of the tumour and surrounding tissue. It is not yet 
known whether IMRT is better than conformal radiotherapy. 
A perfect session of external beam radiation therapy would affect 
only the targeted area without causing side effects in surrounding 
organs. Unfortunately, it is impossible to treat a tumour using 
external radiation therapy without affecting the surrounding tissues 
through which the radiation beams must pass.
Brachytherapy (from the Greek brachy, meaning “short distance”) 
is radiation therapy delivered directly to a tumour, or from within 
it, and also known as internal radiotherapy, implant therapy, seed 
implantation or sealed source radiotherapy. Brachytherapy is 
commonly used as a treatment for prostate and cervical cancers 
and can also be used to treat tumours in other parts of the body. 
Brachytherapy can be used alone or in combination with other 
therapies such as EBRT and hormonal therapy.
Brachytherapy requires the placement of radiatioactive sources 
within the tumour under a general or a spinal (epidural) anaesthetic. 
Around 80–100 small radioactive metal “seeds” can be inserted into 
the tumour allowing radiation to be released slowly over about 
six months, after which they are depleted. The seeds are left in the 
tumour and not surgically removed. They are inserted through 
the skin between the prostate and the anus, and guided into the 
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prostate gland. Other methods involve the temporary placement 
of radiatioactive pellets in the tumour for shorter periods over a 
few days or weeks. As the procedures can cause some swelling of 
the prostate, which can lead to blockage of the urethra, a catheter 
is sometimes inserted into the bladder to drain urine. This may be 
removed after a couple of hours or left in place overnight. 
The seeds are not removed and there is little risk of radiation from 
them affecting other people, although the UK’s Macmillan Cancer 
Support organisation does caution that: 
women who are (or could be) pregnant and children should 
not stay very close to you for long periods of time. You should 
not let children sit on your lap, but can hold or cuddle them 
for a few minutes each day and it is safe for them to be in the 
same room. [84] 
A major advantage of brachytherapy is that the irradiation only affects 
a very localised area around the radiation seed implants. Exposure 
to radiation of healthy tissues further away from the sources is 
therefore reduced. In addition, if the patient moves or if there is 
any movement of the tumour within the body during treatment, 
the radiation sources retain their correct position in relation to the 
tumour. These characteristics of brachytherapy provide advantages 
over EBRT – the tumour can be treated with very high doses of 
localised radiation, while reducing the probability of unnecessary 
damage to surrounding healthy tissues.
A course of brachytherapy can be completed in less time than 
other radiotherapy techniques. This can help reduce the chance of 
surviving cancer cells dividing and growing in the intervals between 
each radiotherapy dose. Patients typically have to make fewer visits 
to the radiotherapy clinic compared with EBRT, and the treatment 
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is often performed on an outpatient basis. This makes treatment 
accessible and convenient for many patients. 
No randomised trials comparing the efficacy of these various forms 
of radiotherapy are available.
Hormonal therapy, also known as androgen deprivation therapy 
(ADT) aims to keep cancer cells from getting the male hormones 
they need to grow. It is called systemic therapy because it can affect 
cancer cells throughout the body. Systemic therapy is used to treat 
cancer that has spread. Sometimes this type of therapy is used to try 
to prevent the cancer from coming back after surgery or radiation 
treatment. 
There are several forms of ADT. Orchiectomy is a form of surgery to 
remove the testicles, which are the main source of male hormones. 
This was introduced in 1942 as the first hormonal treatment for 
prostate cancer. Although it involves an operation, orchiectomy is 
considered a hormone therapy because it works by removing the 
main source of male hormones. Despite sounding drastic, this sur-
gery is simple, quick, and has few risks. 
Drugs known as luteinizing hormone-releasing hormone agonists 
(LHRHA) prevent the testicles from producing testosterone. These 
drugs are injected or placed as small implants under the skin every 
one, three or four months. Examples are leuprolide, goserelin and 
buserelin. All are equally effective. They work by stopping the 
pituitary gland from releasing hormones that stimulate testosterone 
production [85]. 
Drugs known as peripheral anti-androgens block the effects of tes-
tosterone in the blood stream on cells in the prostate and elsewhere. 
These drugs include the “utamides” (bicalutamide, flutamide, nilu-
tamide) and cyproterone. These drugs are usually used to boost the 
effects of LHRHA or orchidectomy. 
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So which treatment is best?
There is a shortage of high-level evidence to answer this very obvious 
and reasonable question. The US Preventive Task Force’s 2008 review 
concluded that “Two recent systematic reviews of the comparative 
effectiveness and harms of therapies for localized prostate cancer 
concluded that no single therapy is superior to all others in all 
situations” [86, 87]. This means that if you decide to be treated for 
prostate cancer, you and your doctor will need to consider any pre-
existing problems that you might have which might be relevant to 
the treatment you have. 
For example, men with urinary problems might be advised against 
brachytherapy because it can make these symptoms worse. Men 
with bowel problems would likely be discouraged from external 
beam radiation therapy because it can affect the rectum as well as the 
prostate. Nerve-sparing radical prostatectomy is typically selected 
where high importance is placed on the preservation of sexual 
function. 
Unfortunately, there is no treatment which comes with any assurance 
or even high probability of avoiding serious unwanted side effects.
Will having a radical prostatectomy save your life?
Let us now assume that you have had a biopsy and staging tests that 
indicate an “early stage” prostate cancer (T1 or T2, N0, M0). Should 
you have your prostate removed or should you “watchfully wait” 
under your doctor’s supervision to see if things progress, and then 
consider medical intervention?
In 2005, The New England Journal of Medicine published a study 
of what happened to 695 men diagnosed with early stage prostate 
cancer with an average age of 65 years who were randomised to 
prostatectomy (347 men) or watchful waiting (348 men) [82]. As 
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the men were recruited into the study over several years, the follow-
up periods differed, with an average period of eight years. At the 
time the study reported its results, 83 (23.9%) of the men who had 
had surgery had died from any cause, compared with 106 (30.5%) 
of the watchful waiting group. Thirty (8.6%) of the men allocated 
prostatectomy died from prostate cancer, while 50 (14.4%) of the 
men allocated to the watchful waiting group died from prostate 
cancer. We can put this another way: if 1000 similar men with early 
stage prostate cancer had prostatectomies, then 86 of them will have 
died from the prostate cancer within the next eight years, while if 
1000 similar men were managed with “watchfully waiting” then 144 
will have died from prostate cancer. Radical prostatectomy would 
therefore prevent 58 deaths per 1000 men (an absolute reduction in 
prostate cancer death of 5.8%, but a 40% reduction if you choose to 
emphasise the relative risk reduction – see p17). 
In 2008, the authors of this study reported results from three more 
years of follow-up of the men (when the men had been followed 
for an average of nearly 11 years). By then a total of 137 men in 
the surgery (radical prostatectomy) group had died compared to 
156 of the men in the watchful waiting group. Forty-seven (13.5%) 
of all the men in the surgery group, compared with 68 (19.5%) of 
the men in the watchful waiting group had died of prostate cancer 
[83]. In other words, men who had radical prostatectomy were less 
likely to die from prostate cancer in the subsequent eleven years than 
men managed with “watchful waiting.” The study also found that 
men who had radical prostatectomy were less likely to progress to 
advanced prostate cancer (involving spread of the cancer beyond the 
prostate gland itself).
What are typical side effects of being treated for prostate cancer?
There is a bewildering range of claims and counterclaims made 
about adverse side effects of being treated for prostate cancer. When 
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reading websites set up by specialists offering prostate surgery and 
other treatments, you should note the oblique wording and the 
use of heavily qualified language (“may”, “might”, “should”, “often”, 
“usually”, “commonly”) concerning the lack of problems about 
the treatment that the urologist is offering. Such words are chosen 
wisely by the owners of such websites because no definite or absolute 
claims can be made in advance of treatment as the outcome can vary 
enormously. 
Studies looking at the outcomes of medical interventions, including 
adverse events like serious side effects, should ideally be conducted 
by researchers who have no competing interests in the results of 
such studies. For example, a surgeon evaluating his or her own 
surgical results would always be mindful of the impact of publicity 
that might follow from results that showed high levels of adverse 
outcomes. Also patients may be reluctant to complain, or may have 
little opportunity to complain of side effects to their surgeon, but 
may feel more able to give an accurate picture of adverse effects to 
impartial research staff.
This factor is something that all men should keep very much in mind 
when reading websites or other material that hint that the surgeon 
being described has a strong success record. It is rare for surgeons 
to have independently conducted studies evaluating the history of 
their surgical performance. Many such studies exist but they are 
almost always without identification so that readers are unable to 
know to which surgical practice or surgeon they refer. Surgeons are 
not like musicians or architects whose work can be easily accessed 
on recordings or by looking at buildings.
When a surgeon advises you on the probabilities of various outcomes 
occurring, it is always sensible to compare what you are told to the 
results obtained by independent studies, particularly those which 
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pool together individual studies to provide a synthesis of what a 
whole range of single studies show when considered together. 
The New South Wales study
One very recent study was published by researchers from New South 
Wales. The researchers approached all men aged less than 70 years 
living in NSW, who had been diagnosed with histopathologically 
(laboratory) confirmed prostate cancer, clinical stage T1a to T2c 
with no evidence of lymph node or distant metastases, between 
October 2000 and October 2002, and notified to the NSW Central 
Cancer Registry by May 2003 (or no more than 12 months after 
their diagnosis). In Australia, all pathology companies, hospitals, ra-
diotherapy centres, day therapy centres, and the registrar of births, 
deaths and marriages are legally required to notify all cancer cases 
to the cancer registry in their state. So this is an excellent way of ob-
taining information about all cases of prostate cancer. It is what we 
call “population data” as distinct from data obtained from a particu-
lar hospital, set of hospitals or individual doctor. The latter are not 
generally publicly available, and even if such data are available, they 
may be biased if not all a surgeon’s cases are included in the statistics.
In the NSW study, 3195 men were identified as eligible to take part 
in the study. The 245 doctors treating these men were approached 
to grant permission for the men to be contacted by the research-
ers. Eight doctors refused to allow any of their 366 patients to be 
contacted, and many doctors also declined permission for particu-
lar patients to be contacted. Of the 2658 men whose doctors gave 
permission for contact, 2031 agreed to participate in the study, rep-
resenting 76.4% of those who were invited.
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A control group was randomly selected from the electoral roll to 
enable comparisons with the prevalence of incontinence and impo-
tence problems in men in the community of the same age profile 
who had not had prostate cancer treatment. The table below sum-
marises the prevalence of sexual and continence problems in the 
men at follow-up three years later, showing comparisons between 
the rates experienced by those who had different treatments and the 
control group, who had had no prostate cancer in that time.
Death
As with many surgical operations, the risk of death from prostate 
cancer surgery is small but real. The risk is about 0.5% or one in 200 
[88, 89]. This risk would be influenced by the older age of many men 
undergoing surgery. Advanced age is an important independent risk 
factor for surgical death. A US study of the patient records of 11,522 
men who underwent prostatectomy between 1992 and 1996 found 
that “neither hospital volume nor surgeon volume [i.e. the number 
of patients the hospital/surgeon has operated on] was significantly 
associated with surgery-related death” [90]. So if your surgeon ever 
tries to reassure you about his or her vast experience in performing 
prostatectomies, or assures you that the hospital where the opera-
tion is to be carried out does a high volume of these operations, you 
should know that the evidence suggests that when it comes to death 
in the operating theatre as an adverse outcome, these volumes ap-
pear to be unrelated to the chance of death being reduced. 
Urinary incontinence
The Cochrane Collaboration is an international project designed to 
synthesise high quality research evidence from all over the world. A 
Cochrane review allows people to assess the “take-home” messages 
derived from considering a large number of well-conducted studies, 
instead of just relying on individual studies, which can differ greatly 
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in what they find. If your surgeon or doctor offers you reassurance 
about the improbability of incontinence or sexual problems, it 
would be very wise for you to take note of what the results of all 
studies combined show, and if there is a large difference between 
what you are told and what the combined research results show, 
then you would be wise to be circumspect and ask more questions. 
The Cochrane Library’s 2007 updated review of post-prostatectomy 
urinary incontinence summarised the data on the prevalence of this 
problem as follows:
It is not uncommon for men to be incontinent after prostatec-
tomy. The reported frequency varies depending on the type 
of surgery and surgical technique, the defi nition and quanti-
fication of incontinence, the timing of the evaluation relative 
to the surgery, and who evaluates the presence or absence 
of incontinence (physician or patient). Reported prevalence 
rates of urinary incontinence after radical prostatectomy for 
prostate cancer vary from 5% to over 60%. For example, in 
one study at three months after radical prostatectomy, 51% 
were subjectively wet (self-report) but 36% were wet on pad 
testing (objective). By 12 months, 20% were subjectively still 
wet, but only 16% were classed as wet using objective crite-
ria. After transurethral resection for benign prostate disease, 
urinary incontinence is less common at three months after 
operation (eg 10% needing to wear pads), but longer term 
data are not available. After both types of operation, the 
problem tends to improve with time: it declines and plateaus 
within one to two years postoperatively. However, some men 
are left with incontinence that persists for years afterwards. 
[91]
Table 9 showed that in NSW, compared to the control group, men 
who had been treated for prostate cancer, regardless of the type of 
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treatment, had higher rates of urinary incontinence three years later. 
Twelve per cent of men who had had a radical prostatectomy were 
experiencing urinary incontinence three years later, while rates were 
lower in those who received various forms of radiation.
According to an August 2008 review by the US Preventive Services 
Taskforce [92], one year after surgically removing the prostate gland, 
15–50% of men have persisting urinary problems. Given that prostate 
cancer would not have harmed many of these men – i.e., they would 
have later died from other causes with prostate cancer, but not from 
it – then this widespread burden of unnecessary surgical side effects 
is a major downside of the whole push to have men screened [93]. 
Bowel problems
In the 2009 NSW study which examined men three years after 
diagnosis and treatment, bowel problems were defined in terms of 
response to the question, “Overall, how big a problem have your 
bowel habits been?” with either “moderate” or “big” counting as 
meaning that the person had a bowel problem. Three years after the 
treatment, bowel function was consistently worse for all treated men 
than for men in the control group, but the effect was greatest among 
men treated with radiation therapy (especially external beam radia-
tion therapy). Table 9 shows that the percentage of men bothered by 
bowel problems was higher (about double) among men treated with 
external beam radiation therapy (EBRT) compared to controls. 
Sexual impotence
According to the 2008 review by the US Preventive Services 
Taskforce [92], one year after surgically removing the prostate 
gland, 20–70% of men have reduced erectile function. As we said 
above in the case of urinary incontinence, given that prostate cancer 
would not have harmed many of these men, these widespread side 
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effects of unnecessary surgical treatment are a major weakness of the 
campaign to have men screened.
Can side effects be reduced if a man is treated by an experienced 
specialist?
There is evidence that the risk of the side effects (but not risk of death 
from surgery, see above) of prostatectomy are somewhat lower if the 
surgery is performed in an institution in which more such operations 
are performed and by a surgeon who does relatively more operations 
[90]. The problem here is that consumers are unable to easily find 
out this information, beyond the assurances that they might be given 
by their doctor. It is doubtful that many doctors would have access to 
data on how a given hospital compared to another.
What is the “da Vinci” robotic surgery machine?
The da Vinci robotic surgery machine, used sometimes in prostate 
cancer surgery, is manufactured by US company, Intuitive Surgical. 
Like other laparoscopic approaches, it allows a surgeon to perform 
a prostatectomy through a small incision rather than via the 
traditional “open surgery” approach. In addition, instead of directly 
manipulating the instruments, a surgeon using a da Vinci machine 
sits at a computer console and directs the machine to perform the 
surgery. The machines cost about $3.5m to buy and $300,000 a 
year to maintain [94]. Depending on the surgeon and institution 
involved, robotic surgery prostatectomy can cost in the vicinity of 
$14,000, which is currently not covered by private health insurance 
(although the operation could attract the standard Medicare rebate 
for a radical prostatectomy, which is a small proportion of the cost). 
In 2006/2007, the average cost for hospital and medical services for a 
da Vinci prostatectomy was $14,274, of which Medicare pays $2396 
(see healthtopics.hcf.com.au/Prostatectomy.aspx).
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What is the state of the evidence that robotic surgery is associated 
with better outcomes for patients? As we will see below, there is 
currently poor evidence that robotic surgery is demonstrably better.
Even if it were true that robotic assisted surgery was demonstrably 
better for men than regular surgery, these machines are not widely 
available in Australia, and because of the costs involved, they will be 
therefore difficult for some men to access or afford. As of 9 August 
2010, the da Vinci website shows there to be just eight da Vinci 
machines in Australia (three in Victoria at Epworth Eastern and 
Epworth Richmond private hospitals and one at the Peter McCallum 
Cancer Centre); two in Brisbane (Greenslopes Private Hospital and 
Royal Brisbane); and one each in Perth (St John of God, Subiaco); 
Sydney (St Vincent’s Private); and Adelaide (Royal Adelaide 
Hospital). According to a prostate cancer support group website 
[95], there are just 26 doctors trained in using da Vinci machines in 
Australia (12 in Melbourne, six in Brisbane, three in Adelaide, three 
in Sydney and two in Perth).
With the costs involved in the acquisition and maintenance of the 
machines, there are obvious incentives for those who have invested 
so heavily in them to promote their use. In May 2006, one Sydney 
surgeon using the machine made what today can be seen as an 
astonishingly heroic prediction “I’m convinced that in five years time 
all prostate operations will be done robotically” [96]. Three years 
after that prediction, an unknown but certainly a small proportion 
of men who have had a prostatectomy, have had it done with robotic 
assistance.
One thing we do know is that the numbers of radical prostatectomies 
being performed in Australia are rapidly increasing. According to 
Medicare claims data, the number of radical prostatectomies per 
year increased approximately fivefold between 1999 and 2009. In 
1999, there were 1142 claims for the operation under Medicare 
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(Item numbers 37210 and 37211) and in 2009 there were 6470. 
These data are based on services that qualify for a Medicare benefit 
and for which a claim was processed by Medicare Australia. They do 
not include services provided by hospital doctors to public patients 
in public hospital, or services that qualify for a benefit under the 
Department of Veterans’ Affairs National Treatment Account. 
Medicare statistics are publicly available at www.medicareaustralia.
gov.au/statistics/mbs_item.shtml.
Does robotic-assisted surgery produce less adverse outcomes? 
The da Vinci corporate website states “studies have shown ‘most 
patients’ have a rapid return of sexual function and urinary 
continence” [97]. “Most” could of course mean as low as 51%. 
Australian urologists using the machine also allude to better 
surgical outcomes in their website advertising. Sydney’s St Vincent’s 
Hospital’s Dr Raji Kooner’s website states: “For the patient, da Vinci 
Prostatectomy may result in more complete eradication of cancer, 
retention of bladder control and potency” [98]. The Australian 
Institute for Robotic Surgery website states: 
Robotic-assisted minimally invasive surgery represents an 
extraordinary technological advance for a broad range of 
procedures traditionally requiring open surgery. By enabling 
surgeons to perform complex operations through small 
incisions, it diminishes the level of patient trauma and helps 
dramatically improve patient outcomes. [99]
And another: “The potential for an improved and more accurate 
nerve sparing procedure and preservation of continence”. 
Melbourne’s Professor Tony Costello is one of Australia’s highest 
profile prostate surgeons. His personal website (www.tonycostello.
com.au/benefits/default.asp?source=cmailer) states that the benefits 
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of robotic surgery “may include reduced risk of incontinence and 
impotence”. But then again, they may not.
It is important to note the highly qualified language in these statements 
(“more complete” [than what?], “may result”, “the potential for”). 
So what is the evidence that robotic assisted surgery produces less 
adverse outcomes? In October 2009, the prostate cancer debate took 
yet another interesting turn with a major study published in the 
Journal of the American Medical Association (JAMA) [100] throwing 
a spanner in the works of those who try to play down the extent of 
adverse outcomes from prostate surgery.
The JAMA study of 1938 men followed for five years reported that, 
compared to routine “retropubic” radical prostatectomy, minimally 
invasive prostatectomy performed via robotic surgery “was 
associated with an increased risk of genitourinary complications 
(4.7% versus 2.1%) and diagnoses of incontinence (15.9% versus 
12.2%) and erectile dysfunction (26.8 versus 19.2 per 100 person-
years)”. 
In other words, robotic nerve-sparing surgery being promoted by 
the handful of surgeons who have invested heavily in it actually 
appears to make things worse. Doctors outlaying such investments 
plainly have a massive incentive to keep up a healthy throughput of 
patients using the equipment and one of the ways of doing this is to 
promote the advantages of better surgical outcomes to their patients. 
Dr Phillip Stricker set up the robotic surgery program at Sydney’s 
St Vincent’s Hospital. Following the release of the JAMA study, in 
an October 2009 issue of the online medical newsletter 6 Minutes, 
he stated that he had performed more robotic prostatectomies than 
anyone else in NSW, and argued that the JAMA results reflected 
inexperience in the use of the technology, stating that: “it takes time, 
experience and technique to achieve equal oncological and potency 
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results” and “many of the surgeons who adopt this perform few 
surgeries and therefore never get off their learning curve”.
So what are Australian men to make of such a statement? Dr Stricker 
seems to be implying that the outcomes in Australia, particularly 
those obtained by very experienced surgeons like himself, would be 
different to the results found in the US study. 
In fact, Dr Stricker was an author on a very recent paper which 
compared the results of 502 retropubic radical prostatectomies 
(RRP) with the results of 212 robot-assisted laproscopic radical 
prostatectomies (RALP) performed by him between 2006 and the 
end of 2008 [101]. Stricker and his co-authors reported that when 
it came to urinary incontinence, it took 200 RALP operations “to 
achieve equivalent early continence rates to RRP”. In other words, 
it wasn’t until Dr Stricker (who had performed more than 2000 
RRPs) had performed 200 RALP operations, that the incontinence 
rates he was achieving were equivalent to those obtained by the RRP 
approach.
And what about impotency rates? Interestingly, no results were 
reported. The paper states 
One of the limitations of this study is the short follow-up 
of 11.2 and 17.2 months for RALP and RRP, respectively. 
As a result we have not reported any long-term continence 
outcomes or erectile function in the present study. 
With the NSW-wide data showing two thirds of all men undergoing 
nerve-sparing radical prostatectomy being impotent at three years 
[102], it is reasonable to assume that one-year rates of impotency 
will be substantial.
7To screen or not to screen for prostate 
cancer?
We now turn to the “crunch” issue in this book, where we will try to provide men with the necessary information to assist 
them to make a truly informed choice about whether to get tested 
for prostate cancer. 
What is meant by “screening” for a disease?
Screening is a process of identifying asymptomatic people who are 
at high risk of having or developing a particular disease or condition 
(often called the “target condition”). Screening has been described 
as “putting a population through a sieve” (see www.screening.nhs.
uk/screening). Most people will pass through the sieve (screening 
test). These people are called low risk for the target condition; they 
receive a “normal” test result. Often they are asked to come back in 
a few years for another test. Some people get caught in the sieve. 
They are people who are at high (or at least higher) risk of having 
or developing the target condition. They will be offered follow-up 
tests to see if they really have the target condition or not. Usually the 
majority of them do not have the target condition; their experience is 
described as a “false positive”. However, some people really have the 
target condition (true positives) and they are offered treatment for it. 
The idea is that this early detection and early treatment of the target 
condition will produce better results than waiting for the disease or 
condition to cause symptoms and treating it then. 
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If it’s a good sieve (screening test), it lets through only low-risk 
people and catches all the high-risk people. Unfortunately none 
of our sieves are perfect – there are always some people who pass 
through the sieve who really are high risk and should have been 
caught (false negatives). Likewise not everyone who gets caught 
in the sieve actually has the disease or is at high risk of having it. 
Because our sieves are not perfect, the initial test (the sieve) never 
definitely tells whether the target condition is present or not. It just 
sorts people into low risk and high risk for the target condition. So 
an abnormal screening test always needs to be followed up with 
more investigations to confirm the initial suspicions.
One of the important things about screening is that the people who 
are screened (go into the sieve) are well. They do not already have the 
target condition, or any symptoms of it. If they do, they are not being 
screened, they are instead said to be having a “diagnostic” test to see 
what is the cause of their symptom. For example, a woman with no 
symptoms of breast cancer (such as a breast lump) may be screened 
by a mammogram. If her screening mammogram is abnormal, 
she will then be offered follow-up tests (which may include more 
mammograms, an ultrasound and/or a biopsy) to establish whether 
she has breast cancer or not. These follow-up tests may be called 
diagnostic tests, because they are done to establish a diagnosis, after 
the initial screening test has indicated she has something suspicious. 
A woman who already has a breast lump will also have a diagnos-
tic mammogram to see if the lump is cancer or not. Even though 
it is the same test (a mammogram) this is not screening, this is 
diagnosis because she already has something suspicious (a lump). 
Her mammogram does not lead to the possibility of treating the 
cancer early, before it has caused any symptoms. 
Another very important point about screening is that the screening 
test alone does not deliver any benefit. It is the package of the 
screening test plus early treatment that may deliver a health benefit. 
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Just doing the test is only the first step of a screening program. 
Without an effective program which provides the follow-up test(s) 
and early, effective treatment for people who have the target 
condition, screening cannot possibly do any good. So it is best to 
think of screening as a screening program, rather than a screening 
test. 
In Australia, blood taken from a heel prick of newborn babies is 
routinely screened to help identify over 20 metabolic conditions such 
as phenylketonuria (PKU – an enzyme deficiency disorder which 
if left untreated, can lead to mental retardation); homocystinuria 
(an inherited enzyme deficiency disease involving a build-up of 
the amino acid homocystine which can cause progressive mental 
retardation) and maple syrup urine disease (named after the 
presence of sweet-smelling urine in affected babies. If left untreated, 
infants suffer severe brain damage and eventually die.) 
Screening of adults seeks to find evidence of chronic disease not yet 
causing symptoms and therefore not under medical care and may 
identify risk factors like high cholesterol and blood pressure, genetic 
pre-disposition or early evidence of disease – as is the case with 
colorectal, cervical and breast cancer screening.
Why do we screen for some diseases but not others? 
In 1968, the World Health Organization published what would 
become a classic report in the history of modern medicine [103]. 
It set out a framework for deciding when it is worthwhile to screen. 
While it set out some very useful principles, it has been updated 
several times since as we have learnt more about screening and its 
pitfalls. For example in 2003, the National Screening Unit in New 
Zealand published a short set of criteria (see Table 10). Similar 
criteria have been developed and adopted to guide policy in the UK, 
Canada and the US.
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Table 10: Criteria for assessing screening programs
The condition is a suitable candidate for screening.
There is a suitable test.
There is an effective and accessible treatment or intervention for the 
condition identified through early detection.
There is high quality evidence, ideally from randomized controlled 
trials, that a screening program is effective in reducing mortality and 
morbidity. 
The potential benefit from the screening programme should 
outweigh the potential physical and psychological harm (caused by 
the test, diagnostic procedures and treatment).
The health care system will be capable of supporting all necessary 
elements of the screening pathway, including diagnosis, follow-up 
and program evaluation. 
There is consideration of social and ethical issues.
There is consideration of cost-benefit issues.
Source: www.nsu.govt.nz/files/NSU/Screening_to_improve_health.pdf
These criteria are very important. Although it seems odd, a screening 
program which does not address these criteria may in fact do more 
harm than good. This is because screening is done to well people, 
so there is a real possibility of doing harm if the screening test or 
the following tests or the treatment for the target condition carry 
important risks. For this reason there is now broad agreement 
among expert groups that there must be “gold standard” evidence 
(mostly this means evidence from randomised controlled trials) that 
detecting disease early and treating it earlier than would otherwise 
have happened must reduce deaths or improve quality of life. In 
short, if treating a person’s disease at a very early time makes no 
positive difference to their life, why would you do it? You would be 
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running the risk of giving people only more “disease-time” rather 
than more lifetime. The idea of adverse effects (or harmful effects) of 
screening is quite counterintuitive. But it is reasonable to think that 
all screening will do some harm. 
Sometimes the harm is limited to the anxiety and inconvenience 
of undergoing the screening test. However it is vital to appreciate 
that screening is actually a “package deal” of early detection and 
early treatment if disease or pre-disease is found. If you don’t go 
on to treat what you find, there can be no benefit of screening. For 
example, what is the point of finding out your child has PKU if you 
are not going to do anything to modify their diet? Similarly is there 
really any point in finding out early you have breast or bowel cancer 
if you don’t intend to treat it? Therefore the adverse effects of treating 
screen-detected disease have to be considered as adverse effects of 
screening. And that’s very important in prostate cancer screening 
because as we saw earlier, adverse effects of follow-up tests and 
treatments for prostate cancer are common and can be severe. 
The side effects of prostate cancer treatment are especially relevant 
when thinking about the “package deal” of prostate cancer screening 
because of the big reservoir of indolent (non-harmful) prostate 
cancer that we talked about before. This big reservoir of indolent 
prostate cancer in the population means that if we screen whole 
populations of men for the disease, we will find it in many of them. 
If we treat all those people, there is enormous potential to cause 
harmful effects in many men. This means it’s especially important in 
the case of prostate cancer screening to carefully consider whether 
the benefits of screening are likely to outweigh the harms. Soon we 
will take a detailed look at what we really know about the benefit of 
prostate cancer screening.
Health agencies around the world are increasingly recognising that 
many people want to be involved in decisions that affect their own 
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health. Many people no longer want their doctor or their government 
to decide for them. Especially in “close-call” decisions where the 
beneficial effects and harmful effects may be finely balanced and 
in decisions where personal preferences may strongly influence 
what a person wishes to do, people want to have a say. Screening 
for prostate cancer is perhaps the best example available of such a 
“close call” and of what people studying this phenomenon call a 
“preference-sensitive decision” [104]. The US Preventive Services 
Taskforce assessment of the evidence for and against PSA screening 
concluded: “the current evidence is insufficient to assess the balance 
of benefits and harms of prostate cancer screening in men younger 
than 75 years”. In short, it is a close call; there are potential benefits 
and harms, and whether you think the benefit is worth the risk 
is a matter of personal judgement. This is why the Taskforce, and 
other health agencies such as Cancer Council Australia, Andrology 
Australia, the UK National Screening Committee and the National 
Screening Unit in NZ all suggest that men should be adequately 
informed about the pros and cons of PSA screening before going 
ahead with a PSA screening test. 
What is the benefit of screening for prostate cancer?
Let’s now take a careful look at what we really know about whether 
screening for prostate cancer saves men from dying early from 
prostate cancer. We will look at a “randomised clinical trial” or 
a “randomised controlled trial” in relation to prostate cancer 
screening to see how do these trials differ from other “studies” about 
the effectiveness of screening.
In short, “randomised clinical trials” or “randomised controlled 
trials” provide a much higher level of evidence than other 
“observational studies”.
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Many research reports published in the medical literature are 
what are known as “observational studies”. An example of a basic 
observational study would be when a group of people who smoke 
are followed for a long time, maybe 20 years, to see how many 
people develop lung cancer, heart disease and so on. Their results 
are compared with a control group of non-smokers who are also 
followed for the same time. The temptation is to see any differences in 
the disease patterns of the two groups as being attributable to (here) 
the smoking and nothing else. While these studies are sometimes 
very important they have a big weakness, which is that you can 
never be sure that the exposed group (in this example the smokers) 
aren’t different in some important way from the control group (in 
this example the non-smokers). For example, the non-smokers may 
be healthier in other ways such as exercising more or eating better, 
and it could be these differences that are important rather than the 
smoking itself (although with this example, the weight of evidence is 
overwhelming that smoking is so risky that it overwhelms all other 
considerations). 
We now have many examples of how we have been misled by 
relying on these kinds of observational studies. A recent example 
was hormone therapy (HT) and heart disease. On the basis of 
observational studies, it was long believed that HT should lower 
the risk of heart disease in post-menopausal women and on this 
basis many women around the world were prescribed HT for many 
years for this and other possible benefits. However when the big 
randomised controlled trials were finally done, it was clear that 
HT does not prevent heart disease in these women and may even 
increase the risk. In short, we learnt the hard way that relying on 
observational studies to decide what works in health care isn’t good 
enough. And this is particularly true of screening when it’s very 
easy to be misled by observational studies as there can be many, and 
subtle, differences between screened and non-screened people. 
96
So instead we rely on randomised controlled trials (RCTs) in prostate 
cancer screening. These provide much stronger evidence because we 
compare two groups of people – men who have been allocated at 
random (in a process like a lottery) to be screened with men who 
have been allocated at random to no screening. This means there 
shouldn’t be any important differences between the groups we are 
comparing other than participation in prostate cancer screening.
With an RCT examining the power of PSA testing to save lives, 
men in the at-risk age group (over 50) who have not had a PSA test 
are randomly allocated either to the “intervention” group (i.e. they 
will be asked to have a PSA test every year or few years) or to the 
“control” group (i.e. they are not given a PSA test). The men in both 
groups are then followed by researchers over a number of years to 
see what happens to them. Here, the main outcomes of interest are 
simply “what proportion of men in the intervention and control 
groups develop prostate cancer, and what proportion die from it?” 
When it comes to RCTs examining the impact of PSA screening 
on death from prostate cancer, the first challenge is to find large 
populations of men who have not already had a PSA test. In the 
USA, the promotion and uptake of PSA screening has been so 
large that a recent long-awaited RCT examining whether prostate 
screening saves lives was badly affected by many of those who were 
assigned to the “no screening group” in fact getting screened. “Rates 
of screening in the control group increased from 40% in the first 
year to 52% in the sixth year for PSA testing and ranged from 41 to 
46% for digital rectal examination” [105]. This “corruption” of the 
control group badly affected the ability of the study to test whether 
screening made any difference in preventing death. The published 
results of the US trial showed no survival benefit from screening but 
because of this trial “corruption”, that study provides little insight 
into whether screening “works”. 
97
Does screening for prostate cancer save lives?
Our knowledge of this advanced significantly in 2009 with 
the publication of a major nine-year-long study, the European 
Randomized Study of Screening for Prostate Cancer (ERSPC) [18]. 
In this large RCT study, the prostate cancer death rate in men who 
were screened was compared with the rate in men who were not 
screened. If early detection were beneficial, we would expect that in 
the screened group, that there would be a lower rate of death from 
prostate cancer because many life-threatening cancers would have 
been detected early and the men put through treatment. If it were 
true that early detection and treatment of men saved lives, the rate 
of death from prostate cancer in the screened men should be lower 
than in the non-screened men.
The ERSPC [18] commenced in the early 1990s. The study included 
182,000 men aged 50 to 74 years from seven European countries. 
Some of these men were randomly assigned to a group that was 
offered PSA screening at an average of once every four years (average 
2.1 tests in the nine years). Others were assigned to a control group 
that did not receive such PSA testing. The primary outcome of 
interest to the study authors was the rate of death from prostate 
cancer. 
During a median follow-up of nine years, the cumulative incidence 
of prostate cancer diagnosed in the screened men was 82 per 1000 
men and 48 per 1000 men in the control group. Basically this means 
that in the nine years after the men were first screened, nearly double 
the rate of prostate cancers was found in men who were screened 
at an average of once every four years than was found in the men 
who were not offered screening. The prostate cancers found in the 
non-screened control group would have been found because some 
of these men would have experienced symptoms and gone to see 
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a doctor. Investigations would have then found prostate cancer in 
these men. 
So far then, we can say that by screening lots of men, we will find 
nearly twice as many histologically (laboratory) confirmed cancers 
in those screened men than in men who don’t get screened but who 
present to doctors with symptoms which are then investigated and 
found to be cancer. But what we really need to know is how many 
men in the screened and unscreened groups died from prostate 
cancer in the nine years of the study, the main focus of interest.
The results were 2.94 deaths per 1000 men in nine years in the 
group of screened men. In the control group, there were 3.65 deaths 
per 1000 men in nine years. The difference means that screening 
prevented just 0.71 deaths per 1000 men over nine years. This is 
about a 20% reduction (in relative terms) in the risk of dying from 
prostate cancer (0.71/3.65). Now that might not sound very much, 
but nine years isn’t very long in the course of a slow disease like 
prostate cancer. Also as we can readily see, dying from prostate 
cancer is uncommon in men this age, so as we expect, the death 
rate is low in both groups. In other words it is hard to see a big effect 
because the outcome is relatively uncommon to start with.
This compares well with the results of randomized studies of 
mammographic screening for breast cancer in women. Systematic 
reviews of these trials conclude that among women aged 50–69 years 
screening with mammograms produces a relative benefit of about 
15% [106].
The key issue that all men need to consider, however, is the balancing 
of benefits versus harms. So the ERSPC study found that we can 
reduce the risk of dying from prostate cancer from 3.65 deaths per 
1000 men over nine years to 2.94 deaths per 1000 men over nine 
years. The price of this modest benefit is the extra numbers of men 
diagnosed with and treated for prostate cancer. Instead of having 48 
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per 1000 men affected by a prostate cancer diagnosis and treatment, 
as in the control group, there were 82 men affected in the screened 
group, in order to prevent less than one death per 1000 men. Whether 
you think that is a reasonable price to pay depends on how you feel 
about the psychological and physical side effects of having a prostate 
cancer diagnosis and treatment (more on that below).
The investigators of the study used these numbers to calculate that 
1410 men would need to be screened and 48 additional cases of 
prostate cancer would need to be treated to prevent a single death 
from prostate cancer. For some readers, this might be a bit hard to 
follow. Put another way, suppose these 48 men were to gather in 
one room. Each of them would be convinced that the detection and 
treatment of their prostate cancer had saved their life. And 47 of the 
48 would be wrong. 
The following may also help. The New York Times ran a report on PSA 
screening on 19 March 2009 [107] describing the study as “the first 
based on rigorous randomized trials”. In summarising the results, 
the NYT quoted Dr Peter Bach, a physician and epidemiologist at 
Memorial Sloan-Kettering Cancer Center. Bach suggested that one 
way to think of the results of the European trial was to consider a 
man having a PSA test that needed further investigation: 
It leads to a biopsy that reveals he has prostate cancer and 
he is treated for it. There is a one in 50 chance that in 2019 
or later he will be spared death from a cancer that would 
otherwise have killed him. And there is a 49 in 50 chance 
that he will have been treated unnecessarily for a cancer that 
was never a threat to his life.
Before we leave this study, some other results from it were that 
in the screening group, 82% of men accepted at least one offer of 
screening. During the trial, 126,462 PSA-based tests were performed 
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on men in the screening group. In total, 16.2% of these tests were 
positive and 85.8% of the men with positive PSA results took up 
the recommendation to have a biopsy. Of the men who underwent 
biopsy, 75.9% had a false positive result (in other words, their 
elevated PSA did not translate to laboratory confirmed prostate 
cancer). The proportions of men who had a Gleason score of 6 or less 
were 72.2% in the screening group and 54.8% in the control group, 
and the proportions with a Gleason score of 7 or more were 27.8% 
in the screening group and 45.2% in the control group. This is to be 
expected because screening detects cancers earlier, and also, as we 
have seen, finds many low grade cancers.
While we have tried to explain the complexities of the European 
trial carefully to maximise its comprehensiveness to men without 
epidemiological training, we appreciate that for some its meaning 
will still be unclear. Over the next pages we present the “take-home” 
messages in graphic form via diagrams with a single dot representing 
one of a 1000 men. We hope this information will assist in your 
understanding.
Source: Data from the European Randomized Study of Screening for Prostate 
Cancer; illustrations by Erin Mathieu, Sydney School of Public Health, University 
of Sydney
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The 2010 Swedish Göteborg study
The Göteborg (Sweden) trial was a randomised controlled trial in 
which men aged 50–64 were randomly allocated to no screening 
or PSA screening every two years. After 14 years of follow-up, the 
study found that PSA screening reduced the men’s chances of dying 
of prostate cancer by nearly half. Over 14 years, 0.5% of the men in 
the screened group (that is 0.5 per 100 men, or one man in every 200 
men) died from prostate cancer compared with 0.9% of the men in 
the control group who were not screened (0.9 per 100 men or just 
under one in every 100 men). Being screened also (unsurprisingly) 
increased the men’s chances of having prostate cancer diagnosed; 
over 14 years, 12.7% of the men in the screened group were 
diagnosed with prostate cancer compared with 8.2% of the men 
in the control group. Treatments for screening detected cancers 
included radical prostatectomy (about 40%), radiation therapy (8%), 
hormone therapy (7%), surveillance followed by treatment (15%) 
and surveillance only (about 30%). 
Expressed another way, the results of this study were that compared 
to a situation of no screening, 293 men need to be invited for PSA 
screening and 12 additional men will be diagnosed with (and treated 
for) prostate cancer to prevent one death from prostate cancer over 
14 years. 
These results are considerably better than those obtained in the 
European multi-nation trial. So which study is more important 
in the Australian debate? Which “take-home” message is most 
important for Australian men to consider? A commentary [33] 
published in Lancet Oncology in the same issue as the trial results 
sought to answer the question “why are there these diff erences be-
tween ERSPC and Göteborg?” The University of Cambridge’s David 
Neal addressed this important question this way:
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Probably the most important points are the longer length of 
time since randomisation and the younger age at screening 
than in the ERSPC, in a national context of a low baseline 
rate of PSA testing before the study ... The [Göteborg] study 
by Hugosson and colleagues might be generalisable to pop-
ulations that have not had prior extensive PSA testing, but 
probably not generalisable to populations that have had such 
testing – eg, in the Göteborg study only 56% of cancers were 
low-risk according to the D’Amico criteria, by contrast with 
tumours found in the second or additional rounds of screen-
ing in the ERSPC, and particularly with tumours found in 
the course of PSA testing in the USA, where typically low-
risk cancers would be found in 75% of patients.
This point was also made in a commentary published by the US 
National Cancer Institute:
During the course of the trial, the state of prostate cancer 
screening in Sweden was “very different from the situation 
in the United States right now,” explained Dr. Eric Klein, 
chair of the Glickman Urological and Kidney Institute at 
the Cleveland Clinic. “It’s comparable to when PSA was 
introduced in the United States in the late ’80s. Now we have 
a heavily screened population, which is why it makes sense to 
build on the results of this trial to further refine our screening 
efforts to identify men at risk for potentially lethal cancers.” 
(see www.cancer.gov/ncicancerbulletin/071310/page5)
Like the USA, Australia is a nation which has had extensive “de 
facto” screening of the population for at least 10 years with more 
than 50% of men having been tested at least once [16]. This means 
that the Australian population, many of whom have already been 
tested, might be expected to show less benefit of screening than was 
found in Goteborg.
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What are the harmful effects of screening for prostate cancer?
Overdiagnosis: cancer treatments you didn’t need
As we have emphasised throughout the book, there is a big risk with 
PSA testing of dredging up cancers that would have remained silent 
and not caused symptoms throughout life. These cancers would only 
be found if the person happened to have an autopsy after they died 
(or if they were screened for prostate cancer).
These cancers are called overdiagnosed cancers. Unfortunately our 
tests are not yet good enough to distinguish between overdiagnosed 
cancers and symptom-causing, life-threatening cancers. So we offer 
treatment to everyone with prostate cancer. These cancer treatments 
commonly have adverse effects and sometimes those adverse effects 
can be really bad for a person’s quality of life; they can be long lasting 
or even life threatening. This makes overdiagnosis and consequent 
overtreatment the number one harmful effect of prostate cancer 
screening.
The US Preventive Health Task Force’s 2008 review of the evidence 
[13] on prostate screening concluded that 
Modeling studies based on U.S. incidence data suggest over-
diagnosis rates ranging from 29% to 44% of all prostate 
cancer cases detected by PSA screening [108]. Because 
patients with ‘pseudo-disease’ receive no benefit from, and 
may be harmed by, prostate cancer screening and treatment, 
prostate cancer detection in this population constitutes an 
important burden.
Thanks to the results from the ERSPC nine-year trial of screening 
[18], we know that about one in 48 men with screen-detected prostate 
cancer will have death from prostate cancer prevented by screening 
(see above). This means the other 47 men have prostate cancer which 
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is overdiagnosed and overtreated, in the sense that it would not have 
killed them had it not been found and not treated. Recall however, 
that the follow-up time of the European trial was only nine years. It 
is possible that had the trial gone for longer (say 20 or 30 years) more 
of these 48 men may have benefited and had a prostate cancer death 
averted. This seems very plausible because as we saw earlier, prostate 
cancer deaths increase with age. On the other hand it’s possible the 
number of prostate cancer deaths prevented might not have got any 
greater had the trial gone for longer. We just don’t know. 
As we saw, the Göteborg study published data on the number of men 
who could be expected to benefit from screening, that is, prevent 
death from prostate cancer. They estimated that about one in 12 men 
with screen-detected prostate cancer will have death from prostate 
cancer prevented by screening within a time frame of 14 years. This 
means only 11 men would have been overdiagnosed and overtreated 
prostate cancer. This better result is likely due to a combination of 
factors including the longer length of follow-up time (14 years rather 
than nine years) and the difference in study population (that is men 
who were largely unscreened for prostate cancer). It is likely that 
the numbers for Australian men would lie somewhere between these 
two estimates. 
What we do know is that, regardless of which study you elect to put 
your faith in, the vast majority of men who have prostate cancer 
found by PSA testing do not benefit, or in other words, do not have 
a prostate cancer death prevented. It’s also pretty clear that if you 
have screening-detected prostate cancer found and treated you 
are much, much more likely to be experiencing overdiagnosis and 
overtreatment than you are to be having a prostate cancer death 
prevented.
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False alarms 
While overdiagnosis may be the biggest downside of PSA screening, 
false alarms are a considerable problem too. In the European study, 
16% of PSA tests were abnormal leading men to have a biopsy. About 
a quarter of these men were found to have prostate cancer on their 
follow-up biopsy. In other words, about 75% (three quarters) of men 
who had a biopsy triggered by a raised PSA test result experienced a 
false alarm [18]. This means they had an abnormal PSA test result but 
their subsequent prostate biopsy showed no cancer. There are both 
psychological and physical downsides of having a false alarm. Some 
people describe it as the scariest time of their lives. For most, it is at 
least inconvenient, uncomfortable and anxiety provoking to some 
extent [109]. While most people (more than 90%) do not experience 
any important physical adverse effects of the biopsy, a few people 
(less than 1%) suffer important complications particularly infection, 
which can be serious enough to require intravenous antibiotics and 
hospitalisation [87]. 
It is important to remember that the chance of experiencing a false 
alarm increases as you have more screening tests. So while the 
chance of having a false alarm is in the range 3–10% following one 
PSA test, if you have tests on a regular basis (say yearly or every two 
years) the chance of having a false alarm after one of them becomes 
quite high over a “lifetime” of screening. 
Make your own choice: weighing up the benefits and harmful 
effects of prostate cancer
As mentioned earlier, there is considerable interest in providing 
men with decision tools to help them weigh up the benefit versus 
risks of PSA screening. A number of these “decision aids” have been 
developed and tested in the US, Canada and the UK. One such 
decision aid, Prosdex, was developed and evaluated in Wales. It is 
available for free online at www.prosdex.com 
8Some further questions and answers
What is the difference between “screening” and “testing” for 
prostate cancer?
As explained, “screening” means that people with no signs or symptoms of disease are urged to undergo a test to see if they 
have that disease. Because (except in rare circumstances) people 
cannot be compelled to be screened, governments sometimes mount 
large-scale public awareness campaigns designed to inform and 
persuade those people for whom screening is relevant to go to either 
a special screening service or to see their doctor (if the screening can 
be done in a doctor’s rooms). Essentially then, screening is testing 
people on a mass scale who have no symptoms of disease to see if 
indicators of disease may be present. 
Those who try to distinguish “testing” from “screening” are in effect 
playing semantic games. Those urging that men be tested seldom use 
the term “screening”, but by directing the message at all men aged 
over 50, their intention is to effectively promote wholesale screen-
ing. They are in fact promoting screening but calling it “testing”. 
They are often aware of the long list of expert bodies (see p7) which 
have examined the wisdom of promoting screening and concluded 
that it is not a policy that should be promoted. But these groups are 
seeking to have it both ways by rejecting “screening” but supporting 
mass testing – in effect the same thing. A good example of this is 
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the current policy of the Urological Society of Australia and New 
Zealand. Their policy states: 
1. Prostate cancer is a major health problem and is the 
second leading cause of male cancer deaths in Australia and 
New Zealand. The Urological Society of Australia and New 
Zealand (USANZ) currently does not recommend the use 
of mass population‐based Prostate Specific Antigen (PSA) 
screening as public health policy, as published studies to 
date have not taken into account the cost effectiveness of 
screening, nor the full extent of over‐detection and over‐
treatment.
2. However, based on recent data from one of two large 
randomised screening studies, there was a reduced risk of 
prostate cancer death with PSA testing and treatment in 
those patients in the 55–69 year age group after 7–8 years. 
Therefore PSA based testing, together with digital rec-
tal examination (DRE), should be offered to men in this 
age group, after providing information about the risks and 
benefits of such testing. [110] [our emphasis]
This policy is plainly having a bet each way. It agrees that screening 
all men is not a good idea for the reasons we explain in detail in this 
book (overdetection and overtreatment) but in the very next para-
graph, states that PSA “testing” should be “offered” to men after age 
55. This is simply a “Clayton’s” screening policy: promoting screen-
ing when you are not promoting it. 
If women are screened for breast cancer, shouldn’t men be 
screened for “their” cancer too?
Women have their cancer screening tests (for cervical and breast 
cancer) and the Australian government recommends that all people 
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aged over 50 be screened regularly for colorectal (bowel) cancer, 
so doesn’t it makes sense that men should be screened for prostate 
cancer?
In media coverage of the disease, men are repeatedly told they 
are not “being a man” if they don’t get tested. This is an argument 
frequently advanced by prostate screening advocates. Its subtext 
is that women are somehow more sensible about their health than 
men because more of them are attuned to regularly doing the 
sensible thing and checking for cancer. The simplistic logic runs 
that men should behave like women and line up to be tested too. 
This argument ignores any consideration of all the evidence that 
we have summarised, and ignores the rather important difference 
that the best available evidence shows a modest benefit of screening 
which must be weighed against the substantial risk of harm through 
overdiagnosis and overtreatment. 
The parallel with mammography screening is an interesting one. 
Both PSA screening and mammography screening are double-edged 
swords. Both have a benefit (reduced chance of dying from cancer) 
and both have adverse effects which range from mild to severe. 
Like PSA screening we have evidence from randomised trials that 
mammography screening reduces women’s chances of dying from 
breast cancer. The effect is a little different, however, because breast 
cancer is a more common cause of death among women in their 40s, 
50s and 60s than prostate cancer is among men in these age groups 
(as we have seen, most prostate cancer deaths occur in men aged 
over 70, and the average age of death from prostate cancer is almost 
80). So compared to PSA screening, more relatively young women 
benefit from mammography screening. 
Breast cancer screening has downsides too, just as we have seen 
with prostate cancer screening. A woman who has mammography 
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screening may experience a false alarm by receiving an abnormal 
result on her mammogram which turns out not to be breast cancer, 
just like a man may get a high PSA level which turns out not to be 
prostate cancer. It may take several tests, often involving a biopsy, to 
confirm she does not have breast cancer. This can be very anxiety 
provoking. 
More importantly, overdiagnosis and overtreatment are also problems 
with mammography screening. Strange though it may seem, a 
woman may be diagnosed with screen-detected breast cancer which 
is indolent and never destined to become life threatening. In fact it 
is estimated that about 25–30% of breast cancers found by screening 
may be like this [111, 112]. Because we can’t distinguish aggressive, 
life-threatening breast cancer from indolent breast cancer, all women 
diagnosed with breast cancer are offered treatment. In this way, the 
overdiagnosis becomes overtreatment. And as with prostate cancer, 
a diagnosis of breast cancer can have profound psychological effects, 
and treatments for breast cancer may have serious adverse physical 
effects. 
With PSA screening, 12–50 extra men may be diagnosed with prostate 
cancer for each man whose death from prostate cancer is averted by 
screening. With mammography screening there is also a wide range 
of estimates about how many extra women are diagnosed with and 
treated for breast cancer. Some researchers estimate that two extra 
women are diagnosed with breast cancer for each woman whose 
death from breast cancer is averted by mammography screening. 
Others estimate 10 extra women are diagnosed with breast cancer 
for each woman whose death from breast cancer is averted [113]. 
This means, the balanace of benefits to harms of screening for breast 
cancer is better, as fewer extra women are treated to prevent each 
death from breast cancer.
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Is improved treatment for prostate cancer responsible for 
decreasing death rates from prostate cancer?
As we demonstrated earlier, death rates from prostate cancer are now 
at about the same level that they were in the 1970s. In 1968 the age-
adjusted death rate for prostate cancer was 35.6 per 100,000 and in 
2007 it was 31 per 100,000 (see Table 4). This small difference follows 
the massive population-wide numbers of men who have been tested, 
investigated and treated for prostate cancer in this 39-year period. 
While it is possible that both improved treatment and screening with 
the PSA test are contributing to the decline in death rates observed 
since the early 1990s (i.e. from a high of 43.7 per 100,000 in 1993 to 
31 per 100,000 in 2007), it seems clear that neither is having a very 
impressive impact. 
Do male doctors and cancer experts themselves get tested for 
prostate cancer?
We know that smoking rates among doctors are the lowest in the 
population: in 1996, just 2% of Australian doctors admitted to 
smoking [114]. So do Australia’s male doctors aged over 50 also 
“take their own medicine” when it comes to being tested for prostate 
cancer? One 2002 study from Victoria has given us information on 
this. It found a minority – 45% – of doctors aged 49 or more had 
been tested [115]. By contrast, a 2006 US study found much higher 
levels of testing (95% of urologists and 78% of non-urologists) [116]. 
Who benefits from mass PSA testing in Australia?
One reason why so many men are now asking to be tested lies in 
the promotional activities of powerful commercial forces which 
strategically promote the benefits of testing but rarely talk about 
the major downsides. The US-based Us Too! International with 
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325 worldwide groups is promoted as a “grassroots” organisation 
established and run by prostate cancer survivors wanting to assist 
men with making an “informed” choice. The Us Too! website lists 
a formidably long list of corporate sponsors in the pharmaceutical, 
medical equipment and pathology service industries [117]. All 
of these industries of course stand to benefit financially by large 
numbers of men being tested and investigated. It is thus predictable 
that the organisation recommends annual PSA tests for men, despite 
the controversies described in this book [118].
The strategy of drug and biotech companies supporting and funding 
apparently spontaneously created grassroots community groups of 
people living with a disease is known as “astroturfing”. Wikipedia 
describes astroturfing like this: 
Astroturfing [refers to] political, advertising, or public 
relations campaigns seeking to create the impression of being 
spontaneous “grassroots” behaviour, hence the reference to 
the artificial grass, AstroTurf. The goal of such a campaign 
is to disguise the efforts of a political or commercial entity 
as an independent public reaction to some political entity 
– a politician, political group, product, service, or event. 
Astroturfers attempt to orchestrate the actions of apparently 
diverse and geographically distributed individuals, by 
both overt (“outreach”, “awareness”, etc.) and covert 
(disinformation) means. Astroturfing may be undertaken by 
an individual pushing a personal agenda or highly organized 
professional groups with financial backing from large 
corporations, non-profits, or activist organizations. Very 
often the efforts are conducted by political consultants who 
also specialize in opposition research.
So when you hear about an organisation promoting prostate cancer 
screening, it is a good idea to try and investigate whether the 
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organisation is sponsored by those who will benefit by large numbers 
of men getting tested.
In Australia, the Prostate Cancer Foundation’s website lists a large 
number of commercial sponsors of the Foundation. Among these 
are four pharmaceutical companies and the da Vinci company, 
which makes the robotic surgical machine discussed earlier. Each 
of the four pharmaceutical companies sells diagnostics (PSA tests) 
or drugs used to treat prostate cancer. That sounds like a natural 
and obvious coincidence of interests. The Foundation is dedicated 
to fighting prostate cancer and the companies have products that are 
involved in that fight. Well and good. But you will look in vain on 
the Foundation’s website or in any of its literature for any detailed 
explanation of the other side of the debate about prostate cancer 
screening that might cause some men to take pause. 
To sum up
Prostate cancer is the second greatest cause of cancer death in 
Australian men after lung cancer. Like most cancers, it is a disease 
which is very uncommon to rare in men aged less than 50, although 
it does of course kill some men in their 40s and 50s. This alone will 
be news to many men who have heard about prostate cancer in the 
news and heard people saying that it can kill men young. 
In fact, prostate cancer is a disease which – more than any other 
cancer – tends to kill men very late in life in the years in which men 
are at higher risk from dying per se (i.e. from any cause). Prostate 
cancer is one of the diseases that brings down the final curtain late 
in life in men. We all will die from some disease. 
In 2010, the Prostate Cancer Foundation of Australia ran television 
ads featuring Australian male celebrities urging all men over 50 and 
men over 40 with a family history of the disease to get tested. The 
line-up included cricketers and footballers in their 30s. Underbelly 
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actor Daniel Amalm, 31, was one of several young men who said 
on camera that prostate cancer can kill men “just like me”. But of 
the 75,433 men who died from prostate cancer between 1968 and 
2007 in Australia, just two (0.003%) were aged 30–34. Given that no 
government anywhere in the world, no peak cancer control agency, 
and no high level, independent review of the evidence has to date 
supported screening, it is important to question campaigns like the 
Foundation’s and consider what it might achieve if it was wildly 
successful. 
Prostate cancer screening advocates repeatedly emphasise that men 
need to make informed decisions about being tested. We wrote this 
book to provide men with information that is rarely included in 
“pro-screening” public information about prostate cancer. 
Some incontestable information that you won’t find on the Prostate 
Cancer Foundation’s website nor in its TV ads is as follows. 
First, prostate cancer is a disease that far more men die with rather 
than from. As we saw, we know this thanks to many autopsy studies 
where men who die suddenly or without having recently seen a 
doctor are examined for cause of death. At autopsy, 10–20% of men 
in their 50s and 40–50% in their 70s have prostate cancer but died 
from other causes. Many men who get tested will thus be found to 
have high PSA levels. Many will be then biopsied and counselled 
to have their prostates removed. This will stop them dying from 
prostate cancer, but the autopsy studies tell us that many of these 
men would not have died of prostate cancer even if their cancers 
had never been found. The problem is that there is no reliable way 
of knowing the benign from the deadly cancers, so overtreatment is 
rampant. 
Second, prostate cancer tends to kill far later in life than other 
cancers. The average age of death for prostate cancer in Australia 
is 79.8 years, while the average age for all male cancers combined 
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other than prostate cancer combined is 71.5 – considerably younger. 
More than half of men who die from the disease are aged 80 or over 
(average age of death for an Australian man in 2007 was 76 years, 
so men who die from any cause after that time are already living 
longer than average); and 82% are aged 70 or more. In 2007, just 
2.8% (83 men) who died from the disease were aged less than 60, 
and 10 (0.1%) were in their 40s. 
Men with family histories of prostate cancer are at elevated risk, 
but it follows that most of these men will have had fathers, uncles 
and grandfathers who died from the disease very late in life. If these 
relatives had not died from prostate cancer, many would have died 
within a few years from other causes because of their advanced age. 
So, what’s the problem with men wanting to do all they can to avoid 
dying young, even if the odds are so low (the chance of a man aged 
40–44 dying from prostate cancer in a year is a stratospheric one 
in 250,000 – worse odds than winning the lottery – while for men 
over 85 it is one in 125)? Thirty years ago, prior to PSA testing being 
available, our death rate from prostate cancer was 33.4 per 100,000 
men. In 2007 it was 31 per 100,000, a decline of 7.2%. The decline 
probably reflects both early detection and better treatment. Yet 
over the same period, the incidence of prostate cancer rose 110% 
from 80.8 per 100,000 to 170 per 100,000, thanks to the aggressive 
promotion of PSA testing, often by those who stand to benefit 
financially by its proliferation. 
The third major problem is that widespread testing leads to widespread 
unnecessary surgery and frequent serious complications. Recent data 
from across NSW show that three years after radical prostatectomy, 
77% of men remain impotent and 12% have urinary incontinence 
compared to 22% and 1% respectively of age-matched men who do 
not have prostate cancer. Many of these men underwent unnecessary 
surgery and now live permanently with the consequences. They tend 
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not to talk publicly about these problems. Trite dismissal of the daily 
lives of thousands of unnecessarily impotent and incontinent men by 
saying, “You can’t have sex in a coffin” is astonishingly arrogant. All 
this is why earlier this year Richard Ablin who discovered prostate-
specific antigen on which the PSA test is based called the promotion 
of widespread testing “a hugely expensive public health disaster”.
In 2009, nine-year results were published from a multi-nation 
European trial of PSA testing. Dr Peter Bach from New York’s Sloan-
Kettering Cancer Center summarised the meaning of the trial for a 
man being treated after testing positive today: 
There is a one in 50 chance that in 2019 or later he will be 
spared death from a cancer that would otherwise have killed 
him. And there is a 49 in 50 chance that he will have been 
treated unnecessarily for a cancer that was never a threat to 
his life. 
Enthusiasts for prostate testing emphasise that the  European trial 
saved lives. It did. But the reduction was from 4.2 to 3.3 deaths per 
10,000 person-years. 
In 2010, further important results were published from a Swedish 
trial of prostate cancer screening. These results put a better 
complexion on the case for screening, finding that as few as 12 men 
would need to be treated to prevent one prostate cancer death in 
that population. But expert commentators on that study suggest that 
Sweden – a nation which has not had comparable proportions to 
Australia of men tested for prostate cancer – is not an ideal nation 
from which to draw lessons that would apply here. 
Telling someone that they have cancer, particularly when the great 
majority of men thus diagnosed would have never died from the 
disease nor had their life in any way affected by the “silent” or indolent 
cancer inside them, can be deadly serious. We saw that a Swedish 
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study found that the risk of suicide after diagnosis of prostate cancer 
was 7.4 times higher during the first week after diagnosis and 1.6 
times higher during the first year after diagnosis, compared to age-
matched men not diagnosed.
Some testing enthusiasts promote the idea that untested men are 
ignorant or in denial. But many men consciously choose to remain 
ignorant of their PSA status after reading widely for themselves. 
Indeed, a Victorian study of GPs aged over 49 found that 55% 
had not themselves been tested. Celebrities have made wonderful 
contributions to raising public health awareness, but this carries 
responsibilities to ensure the public are given the full picture. 
Promoting prostate cancer testing should emphasise both sides of 
the issue, to ensure men make fully informed decisions. 
We hope that you found the information in this book useful and if 
so, would encourage you to send it to other men.
The book is available to download as a free PDF file at: 
hdl.handle.net/2123/6835
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